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1. INTRODUCTION 
1.1 ORAL DRUG DELIVERY [1]:  
Most conventional oral drug products, such as tablets and capsules, are formulated to release the 
active drug immediately after oral administration, to obtain rapid and complete systemic drug 
absorption. Such immediate release products result in relatively rapid drug absorption and onset 
of accompanying pharmacodynamic effects. However, after absorption of the dosage form is 
complete, plasma drug concentration decline according to drug’s pharmacokinetic profile. 
Eventually, plasma drug concentration fall below the minimum effective plasma concentration 
(MEC), resulting in loss of therapeutic activity. Before this point is reached, another dose is 
usually given if a sustained therapeutic effect is desired. An alternative to administering another 
dose is to use a dosage form that will provide sustained drug release, and therefore maintain 
plasma drug concentrations, beyond what is typically seen using immediate release dosage 
forms. 
1.2 MODIFIED DRUG DELIVERY: 
The term modified release drug product is used to describe products that alter the timing and/or 
the rate of release of the drug substance. A modified-release dosage form is defined as one for 
which the drug-release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms such as 
solutions, ointments, or promptly dissolving dosage forms as presently recognized. Several types 
of modified-release drug products are recognized. 
 Modified release delivery systems may be divided conveniently in to four categories: 
A. Delayed release 
B. Controlled release 
i. Sustained release 
ii. Extended release 
C. Site specific targeting 
D. Receptor targeting 
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 A. Delayed Release: 
        These systems are those that use repetitive, intermittent dosing of a drug from one or more 
immediate release units incorporated in to a single dosage form. Examples of delayed release 
systems included repeat action tablets, capsules and enteric-coated tablets where timed release is 
achieved by barrier coating. 
B. Controlled release systems:  
        These systems include any drug delivery systems that achieves slow release of drug over an 
extended period of time and also can provide some control, where this be of a temporal or spatial 
nature, or both, drug release in the body, or in other words, the system is successful at 
maintaining constant drug levels in the target tissue or cells. 
i) Sustained release: 
These systems include any drug delivery system that achieves slow release of drug 
over an extended period of time. 
ii) Extended release: 
Pharmaceutical dosage forms that release the drug slower than normal manner and 
necessarily reduce the dosage frequency by two folds.  
C. Site specific targeting: 
           These systems refer to targeting of a drug directly to a certain biological location. In this 
case the target is adjacent to the effected organ or tissue. 
D. Receptor targeting:  
           These systems refer to targeting of a drug directly to a certain biological location. In this 
case the target is the particular receptor for a drug with in organ or tissue. 
 1.3 EXTENDED RELEASE DOSAGE FORMS [2]: 
            Dosage forms which can reduce at least a two fold reduction in dosing frequency as 
compared to the drug presented in a conventional form, such as solution or a prompt releasing 
conventional solid dosage form are termed as extended release dosage forms. 
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           These products are formulated to make the contained medicament available over an 
extended period of time after administration within its therapeutic range and hence reduction in 
dosing frequency as compared to the conventional dosage forms.  
 
          Comparison of different types of modified release dosage formulations as per plasma 
concentration vs. time can be explained by the following figure. (1) 
 
 
  
 
 
 
 
 
 
      
 
 
 
                                  Figure No.1: plasma concentration vs. time 
          
ADVANTAGES AND DISADVANTAGES OF ORAL EXTENDED RELEASE 
DOSAGE FORMS 
             All sustained release dosage forms have a common goal of improving the drug therapy 
compared to that achieved by their non sustained counter parts. 
 
Advantages 
  Avoid patient compliance problems 
  Employ less quantity drug. 
  Minimize or eliminate local side effects. 
  Minimize or eliminate systemic side effects. 
  Reduce dosing frequency and fluctuation of therapeutic plasma concentration 
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  Obtain less potentiation or reduction in drug activity with chronic use. 
  Minimize drug accumulation with chronic dosing. 
  Improves efficiency in treatment 
  Cures or control conditions more promptly. 
  Improves control of condition i.e., reduces fluctuations in drug level. 
  Improves bioavailability of some drugs. 
  Makes use of special effects in sustained release aspirin for morning relief of arthritis by 
dosing before bedtime. 
 Economy 
 
Disadvantages 
 Dose dumping, toxicity can occur if system fails. 
 Reduced potential for accurate dose adjustments. 
 Need for additional patient education. 
 Does not permit the prompt termination of drug therapy. 
 Cannot exercise any control once the dosage form is administered. 
 
1.3.1 TYPES OF EXTENDED RELEASE PRODUCTS: 
 
(a) Diffusion Controlled Products 
In these a water-insoluble polymer which controls the flow of water and the subsequent 
release of dissolved drug from the dosage form. Both diffusion and dissolution processes are 
involved. In `reservoir' devices, a core of drug is encapsulated with in a polymer coat, and in 
`matrix' systems, the drug is dispersed throughout the matrix. Cellulose derivatives are 
commonly used in the reservoir types, while the matrix material may be plastics, e.g. 
methylacrylate-methyl methacrylate, polyvinyl chloride, hydrophilic polymers such as cellulose 
derivatives or fatty compounds including carnauba wax. Examples of this type of formulation 
include Agon SR, Kapanol and Slow-K. [2,3] 
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(b) Dissolution Controlled Products 
The rate of release of the drug (and there by availability for absorption) is controlled by 
slowly erodible/ soluble polymers or by micro encapsulation of drugs with slowly soluble 
polymers. Once the coating is dissolved, the drug becomes available for dissolution. By varying 
the thickness of the coat and its composition, the rate of drug release can be controlled. Some 
preparations contain a fraction of the total dose as an immediate-release component to provide an 
immediate dose soon after administration. 
 
              The pellet dosage forms of diffusion or dissolution controlled products can be 
encapsulated or prepared as a tablet. Encapsulated pellet products have an advantage that the 
onset of absorption is less sensitive to stomach emptying. The entrance of the pellets into the 
small intestine (where the majority of drug absorption occurs) is usually more uniform than with 
non-disintegrating extended-release tablet formulations. An example of this type of product is 
Fefol [4]. 
 
(c) Erosion Products 
              The release of drug from these products is controlled by the erosion rate of a carrier 
matrix. The rate of release is determined by the rate of erosion. An example of this formulation is 
Sinemet CR. This product, some patients may experience a delayed onset of action after the 
morning dose, compared to conventional levodopa tablets, because of the delayed release of the 
drug. 
 
(d) Osmotic pump systems 
              The rate of release of drug from this drug delivery system is maintained by the constant 
inflow of water across a semi permeable membrane into a reservoir, which contains an osmotic 
agent. The drug is either mixed with the agent or is located in a reservoir. The dosage form 
contains a small hole from which dissolved drug is pumped at a rate determined by the rate of 
entrance of water due to osmotic pressure. The rate of release is constant and can be controlled 
within limits yielding relatively constant blood concentrations. The advantage of this type of 
product is that the constant release is unaltered by the environment of the gastrointestinal tract 
and relies simply on the passage of water into the dosage form. The rate of release can be 
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modified by altering the osmotic agent and the size of the hole. An example of this type of 
product is ALZET. [3,4] 
 
 
Ion exchange systems 
             Some drugs can be bound to ion exchange resins and, when ingested, the release of drug 
is determined by the ionic environment within the gastrointestinal tract. Examples of this type of 
product are Duromine containing the basic drug phentermine complexed onto an anionic resin [4]. 
 
1.3.2 FACTORS TO BE CONSIDER IN DESIGN OF EXTENDED RELEASE 
PRODUCTS: 
             To successfully design extended release drug delivery system for a given drug, 
information about drug like, 
 The properties of the drug, its behavior in biological systems, its biological half life is 
essential. 
 The Absorption, Distribution, Metabolism and Elimination (ADME) characteristics of the 
drug will enable the development of mathematical models to adequately describe the 
transit of the drug in the system. 
 The relationship between the absorption and the blood concentration. 
 The desired profile of therapeutic action with these kinds of segments like rapid rise, 
constant tissue level and rapid concentration. 
 Information related to the tendency of the drug to get accumulated or bound to plasma 
proteins and any body tissue. 
 The route of administration, the dose and the ultimate pharmacological action. 
 Various physical and chemical properties of the drug. 
 
1.3.3 MECHANISM OF EXTENDED RELEASE: 
The rate of release of a drug dispersed as a solid in an inert matrix has been described by 
Higuchi. In this model it is assumed that the solid drug is dissolved from the surface layer of 
device first and this layer becomes exhausted of the drug; the next layer begins to get depleted by 
dissolution and diffusion through the matrix, to the external solution. In this fashion interface 
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between the regions containing dissolved drug and that containing the dispersed drug moves to 
the interior as a front[2,3]. 
 
 
The assumptions which are made in deriving the mathematical models are as follows: 
 A pseudo steady state is maintained during the release. 
 The total amount of drug present per unit volume in the matrix, C0 is substantially greater 
than the saturation solubility of drug per unit volume in the matrix Cs 
 The release media is the perfect sink at all times. 
 Drug particles are much smaller in diameter than the average distance of diffusion. 
 The diffusion coefficient remains constant. 
 No interaction occurs between drug and the matrix. 
          Schematic representation of the physical model used for a planar slab matrix diffusion 
device based on the above assumptions, the change in the amount of the drug released per unit 
area, dM with a change in the depleted zone thickness dh, is 
                       dM = Codh – (Cs/2) dh ------------- (a) 
Where, Co and Cs is the drug present per unit volume and saturation solubility respectively. 
                      dM = (Dm. Cs / h) dt ---------------- (b) 
Where, Dm is the diffusion coefficient of the matrix. 
        If the equation a and b are equated, and solved for h , and that value of ‘h’ was substituted 
back in to the integrated form of equation(b) an equation for M is obtained. 
                    M = [Cs Dm (2Co - Cs) t] 1/2 ------------(c) 
Similarly, a Drug release from a porous granular matrix is described by, 
                    M = [Cα Ds (ε / T) (2Co – ε Cα) t]1/2 --------- (d) 
Where, ε is porosity of matrix, 
T is tortuosity, 
Cα is the solubility of drug in the release medium, 
Ds is diffusion co-efficient of drug in the release medium. 
For the purposes of the data treatment, equation (b) and (c) are conveniently reduced to 
M = Kt1/2 
Where K is a constant, so that a plot an amount of drug released versus square root of time 
should be linear if the release of drug is diffusion controlled. 
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1.4 MULTI PARTICULATE DRUG DELIVERY SYSTEM: 
 
Multi-particulate drug delivery systems are mainly oral dosage forms consisting of a 
multiplicity of small discrete units, each exhibiting some desired characteristics. In these 
systems, the dosage of the drug substances is divided on a plurality of subunit, typically 
consisting of thousands of spherical particles with diameter of 0.05-2.00 mm. Thus 
multiparticulate dosage forms are pharmaceutical formulations in which the active substance is 
present as a number of small independent subunits. To deliver the recommended total dose, these 
subunits are filled into a sachet and encapsulated or compressed into a tablet [5,6]. 
 
Multiparticulates are discrete particles that make up a multiple unit system. They provide 
many advantages over single-unit systems because of their small size. Multi-particulates are less 
dependent on gastric emptying, resulting in less inter and intra-subject variability in 
gastrointestinal transit time. They are also better distributed and less likely to cause local 
irritation. Recently much emphasis is being laid on the development of multiparticulate dosage 
forms in preference to single unit systems because of their potential benefits such as increased 
bioavailability, reduced risk of systemic toxicity, reduced risk of local irritation and predictable 
gastric emptying [7,8].   
 There are many reasons for formulating a drug as a multiparticulate system for example, 
to facilitate disintegration in the stomach, or to provide a convenient, fast disintegrating tablet 
that dissolves in water before swallowing which can aid compliance in older patients and 
children. Multiparticulate systems show better reproducible pharmacokinetic behavior than 
conventional (monolithic) formulations. After disintegration which occurs within a few minutes 
often even within seconds, the individual subunit particles pass rapidly through the GI tract. If 
these subunits have diameters of less than 2 mm, they are able to leave the stomach continuously, 
even if the pylorus is closed. These results in lower intra and inter individual variability in 
plasma levels and bioavailability. 
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 1.4.1 SOME APPROACHES TO MULTIPARTICULATE FORMULATION: 
The site-specific delivery of drugs to the colon has implications in a number of 
therapeutic areas, which include topical treatment of colonic disorders such as Crohn’s disease, 
ulcerative colitis, constipation, colorectal cancer, spastic colon and irritable bowel syndrome. 
Multiparticulates approaches tried for colonic delivery includes formulations in the form of 
pellets, granules, microparticles and nanoparticles. Because of their smaller particle size 
compared to single unit dosage forms these systems are capable of passing through the GI tract 
easily leading to low inter and intra subject variability. Moreover, multiparticulate systems are to 
be more uniformly dispersed in the GI tract and also ensure more uniform drug absorption. 
Multiparticulates may be prepared by several methods. Different methods require different 
processing conditions and produce multiparticulates of distinct qualities. Some of these methods 
may be broadly classified as:  
 Pelletization 
 Granulation  
 Spray drying  
 Spray congealing 
 
 Drug particles may be entrapped within the multiparticulates or layered around them. 
Subsequently, these multiparticulates may be modified in many ways to achieve the desired drug 
release profile. One approach to the modification of drug release profile in multiparticulates is to 
coat them. Reasons for the application of coating onto multiparticulates are to obtain functional 
coats, provide chemical stability, improve physical characteristics and enhance patient 
acceptance. Coats are formed from various polymeric coating materials broadly classified as 
aqueous polymer dispersions, polymer solutions, molten polymers and dry powders. Depending 
on the type of coating material used, functions such as sustained release, targeted release, 
delayed release and pulsatile release can be achieved.  
The most common method used for the application of coating onto multiparticulates is air 
suspension coating. Other methods include compression coating, solvent evaporation, co-
acervation and Interfacial complexation. It is also possible to form coated multiparticulates by 
spray drying and spray congealing.  
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A multiparticulate composition may allow controlled release of the drug over a wide 
range of release rates and permit the release rate to be set at a predetermined rate, such a 
formulation may be formed using a melt-congeal process which maintains the crystallinity of the 
drug during the melt congeal process [7,8,9,10]. 
 
1.4.2 MECHANISM OF DRUG RELEASE FROM MULTI-PARTICULATES: 
 
The mechanism of drug release from multiparticulates occurs in the following ways: 
Diffusion 
On contact with aqueous fluids in the gastrointestinal tract (GIT), water diffuses into the 
interior of the particle. Drug dissolution occurs and the drug solutions diffuse across the release 
coat to the exterior. 
Erosion 
Some coatings can be designed to erode gradually with time, there by releasing the drug 
contained within the particle. 
Osmosis 
In allowing water to enter under the right circumstances, an osmotic pressure can be built 
up within the interior of the particle. The drug is forced out of the particle into the exterior 
through the coating [11]. 
 
1.5 PELLETS: 
 
 
Figure No: 2 
Pellets are agglomerates of fine powders or granules of bulk drugs and excipients. They 
consist of small, free flowing, spherical or semi-spherical solid units, typically from about 0.5 
mm to 1.5 mm and are intended usually for oral administration. Implants of small, sterile 
cylinders formed by compression from medicated masses are also defined as pellets in pharmacy. 
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Pellets can be prepared by many methods, the compaction and drug-layering being the most 
widely used today[12,13,14]. 
 
The most common advantages of Pelletization are [15,16,17,18,19,20]: 
 
 Improved appearance of the product and the core is pharmaceutically elegant. 
 Pelletization offers flexibility in dosage form design and development. 
 Pellets are less susceptible to dose dumping. 
 It reduces localized concentration of irritative drugs. 
 It improves safety and efficacy of a drug. 
 Pellets offer reduced variation in gastric emptying rate and transit time. 
 Pellets disperse freely in GIT and invariably maximize drug absorption and also reduce 
peak plasma fluctuation. 
 Pellets ensure improved flow properties in formulation development. 
 The coating of pellets can be done with different drugs to enable a controlled release rate 
of the formulations. 
 Pellets minimize intra and inter subject variability profiles, unlike the single unit 
conventional dosage form. 
 Successful film coating can be applied onto pellets due to their ideal spherical shape and 
a low surface area to volume ratio. 
 Pellets composed of different drugs can be blended and formulated in a single dosage 
form. 
 Even pellets with different release rates of the same drug can be supplied in a single 
dosage form. 
 Pellets can be divided into different dose strengths without formulation and process 
changes. 
 They can be blended to deliver different incompatible agents simultaneously. 
 They provide different release rates at same or different places of gastro intestinal tract. 
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1.5.1 PELLET FORMATION AND GROWTH:  
The mechanism of pellet formation and growth, the following steps were proposed: 
 Nucleation 
 Coalescence 
 Layering  
 Abrasion transfer.  
 
Nucleation 
Nucleation is a common stage in all pelletization/granulation processes and occurs 
whenever a powder is wetted with liquid. The primary particles are drawn together to form three 
phase air wetted liquid nuclei and are attached together by liquid bridges, which are pendular in 
nature. The bonding strength is improved by reduction of particle size. The sizes of primary 
particles, moisture content, viscosity of  binding particles, wet ability of substrate and the 
processing conditions, such as tumbling and drying rates, influence the size, rate and the extent 
of nuclear formation. Both mass and number of nuclei in the system changes as a function of 
time, which is an important feature of nucleation [13,21,22]. 
             Nucleation followed by a transition phase and the growth mechanism affecting the 
transition region are coalescence and layering. 
 
Coalescence 
              Coalescence is defined as the formation of large sized particles by random collision of 
well-formed nuclei, and the mechanism requires slight excess moisture on the nuclear surface. 
Although the number of nuclei is progressively reduced, the total mass of the system remains 
unchanged during this step. Layering is a slow growth mechanism and involves a successive 
addition of fragments and fines on an already formed nucleus [22]. 
 
Layering 
                In the layering step, the number of particles remains same but the total mass in the 
system increases due to increasing particle size as a function of time. The fragments or fine 
particles can be formed by particle size reduction that occurs due to attrition, breakage and 
shatter. The fines and fragments that are produced through size reduction are picked up by large 
pellets. Production of fines and subsequent coalescence and layering continues until the number 
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of favorable coalition’s declines rapidly, thereby leading to a reduction in the rate of growth of 
the pellets. [13] 
 
Abrasion transfer 
In the ball growth phase the main mechanism affecting the slow growth of agglomeration 
is the abrasion transfer which involves the transfer of material from one granule formed to 
another without any preference in either direction. This situation does not result in a change in 
the total number or mass of the particles. The particles however undergo a continuous change in 
size as long as the conditions that lead to the transfer of material exist. [13] 
 
Manufacturing of pellets directly from powder 
 
                                                          Figure No: 3 
Powder is mixed and moistened with a solvent or binder and the powder bed is set into a 
centrifugal motion (Fluid Bed Pelletizing in the rotor). The impact and acceleration forces that 
occur in this process result in the formation of agglomerates, which become rounded out into 
uniform and dense pellets. The speed of rotation has a direct influence on density and size of the 
pellets. The moist pellets are subsequently dried in the fluid bed. 
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Lipid/Hot Melt Coating [23]: 
 
                                                               Figure No: 4 
 
Lipid/Hot melt coating is a very effective process for the application of waxes and molten 
materials as protective films for manipulating the particle properties. 
Glatt offers Fluid Bed Coating (Top Spray Coating, Bottom Spray and Tangential Spray) 
as a technical solution for coating different particles and tablets. The coating fluid is sprayed 
onto solid materials, which are presented to it. The introduction of process air causes the film 
coating to solidify and a small droplet which is low viscosity ensures that the distribution is 
uniform. The time and energy-intensive evaporation of solvents can be dispensed with by the use 
of molten materials as coating liquids. 
 
1.5.2 PELLETIZATION TECHNIQUES 
 Powder layering 
 Extrusion-Spheronization 
 Compression  
 Solution/Suspension layering 
 Globulation 
 Balling or Spherical agglomeration 
 Melt spheronization 
 Cryopelletization 
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Powder layering[24,25] 
Principle 
 
                                                              Figure No: 5 
 
 It is carried out in Fluid bed Granulator or Tangential spray equipment. 
 During powder layering, a binding solution and a finely milled powder are added 
simultaneously to a bed of starter seeds at a controlled rate. In the initial stages, the drug 
particles are bound to the starter seeds and subsequently to the forming pellets with the 
help of liquid bridges originated from the sprayed liquid. 
 These liquid bridges are eventually replaced by solid bridges derived either from a binder 
in the application medium or from any material, including the drug substance, that is 
soluble in the liquid. 
 Successive layering of the drug and binder solution continues until the desired pellet size 
is reached. Throughout the process, it is extremely important to deliver the powder 
accurately at a predetermined rate and in a manner that maintains equilibrium between 
the binder liquid application rate and the powder delivery rate. 
 If the powder delivery rate is not maintained at predetermined equilibrium levels, over 
wetting or dust generation may occur and neither the quality nor the yield of the product 
can be maximized. 
 Towards the end of the layering process, it is likely that fines may be generated owing to 
potential interparticle and wall-to-particle friction and appears in the final product, there 
by lowering the yield. 
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 The problem can be overcome if the application medium is sprayed on cascading pellets 
at the end of layering process to increase the moisture level at the pellet surface and 
facilitate layering of the fines onto the pellets. 
 
Extrusion-Spheronization [ 26,27,28 ] 
 Extrusion–spheronization is a multistep process involving dry mixing, wet granulation, 
extrusion, spheronization, drying and screening. 
 The first step is dry mixing of the drug and excipients in suitable mixers followed by wet 
granulation, in which the powder is converted into a plastic mass that can be easily 
extruded. 
 The extruded strands are transferred into a spheronizer, where they are instantaneously 
broken into short cylindrical rods on contact with the rotating friction plate and are 
pushed outward to the stationary wall of the processing chamber by centrifugal force. 
 Finally, owing to gravity, the particles fall back to the friction plate, and the cycle is 
repeated until the desired sphericity is achieved. 
 
Principle of the Granulate Spheronizing Process: 
 
Figure No: 6 
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Principle of the Extruded Product Spheronizing Process: 
 
Figure No: 7 
Compression: 
 It is a type of Compaction technique for preparing pellets. Pellets of definite sizes and 
shapes are prepared by compacting mixtures or blends of active ingredients and 
excipients under pressure. 
 This process can be achieved by using extrusion-spheronization technique. 
 
 
Solution/Suspension layering [29,30]: 
Principle 
 Layering processes involve loading solid inert cores with drugs and/or excipients. Inert 
cores are placed in a suitable vessel such as a coating pan or a fluid bed and are layered 
according to different methods. 
 
Figure No: 8 
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 Some methods consist of spraying onto the cores a solution/suspension containing both 
drug and binding agent. Others are based on layering the drug directly in powder form 
where drug loading occurs by gravity and adhesion is ensured by a liquid binder sprayed 
onto the cores. 
 The layering process is particularly suitable for production of small drug loaded units, 
multiples of which are placed into capsules for patient delivery. 
 In the case of spherical inert cores such as non-pareils, the layering techniques from 
solution/suspensions produce homogeneous drug loaded particles, which retain an 
approximately spherical shape. 
 
Fluidized bed Coater: 
Principle: 
Fluidized bed coating is a process that takes place inside a fluidized bed where by a coat 
is introduced to cover the intended object in order to protect or modify its behavior. Particulate 
coating is a form of fluidized bed coating involving the coating of solid particles inside the bed. 
In the process, a layer is deposited onto the surface of fluidized solid particles by spraying with a 
solution of the coating material. The fluidizing gas is also used to dry the deposited solution to 
form a coat on the surface of the particle. Fluidized beds are used for coating because of their 
high energy and mass transfer. Fluidized beds for film coating can be divided into three groups. 
Types: 
 Top spray 
 Tangential (Rotating disk granulator)  
 Bottom spray (Wurster Process) 
 
Fluid Bed Coating Flow Chart: 
 
Figure No: 
9 
Top 
spray: 
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 This process is used for general coatings right up to enteric coating. 
 With top spray coating in the fluid bed, particles are fluidized in the flow of heated air, 
which is introduced into the product container via a base plate. 
 The coating liquid is sprayed into the fluid bed from above against the air flow 
(countercurrent) by means of a nozzle. Drying takes place as the particles continue to 
move upwards in the air flow. 
 The expansion chamber is lengthened to allow powder to remain fluidized longer and to 
move with a higher velocity, so that agglomeration is minimized. The expansion chamber 
is conically shaped to allow uniform declaration of air stream. The filter housing is larger 
and designed to shake the fines back into the bed interrupting fluidization; this reduces 
agglomeration tendencies. 
 The nozzle is positioned low in the expansion chamber so that coating material impinge 
on the fluidized particle a short distance from the nozzle, this reduces droplet spray 
drying and provides for longer subsequent drying of the coated particles. 
 
Tangential spray: 
 
 Ideal for coatings with high solid content. 
 These techniques have been extended for coating operations and combined with an 
expansion chamber to form the rotating disk granulator and coater fluid bed device. The 
basic design employs a rotating disk in the product container. 
 The disk can be moved up or down to create a variable slit opening between the outer 
perimeter of the disk and the sidewall of the container. Air is drawn into the product 
container through the slit under negative pressure. 
 This fluidizes the material along the circumferential surface of the product container. At 
the same time the disk rotates at varying speeds and moves the product by centrifugal 
force to outer portions where it is lifted by fluidizing air stream into the expansion 
chamber. 
 As the material decelerates, it descends to center of the disk and repeats the same 
sequence. 
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 The fluidization pattern is often described as a spiraling helix or rope-like pattern around 
the inside of rotor chamber. Spray nozzles can be immersed in the bed of fluidized 
material and spray applied in tangential fashion with respect to the particle flow. 
 Very thick film layers can be applied by means of the rotor method. 
 
Bottom spray: 
 
 This process is particularly suitable for a controlled release of active ingredients. In the 
Wurster process, a complete sealing of the surface can be achieved with a low usage of 
coating substance. 
 Inside the container a second cylinder (coating partition) which is raised slightly above 
the perforated plate, centered. Below this partition a spray nozzle used to dispense the 
coating solution is fitted in the base plate resulting in a spray pattern that is concurrent 
with the air feed. 
 The perforated plate is designed with large holes in the area under the coating partition 
and smaller holes in the remainder of the plate, except for one ring of large holes at the 
perimeter. 
 
 The design allows the substrate particles to be pneumatically transported upward through 
the coating partition and downward outside this partition. 
 By using a wurster cylinder and a base plate with different perforations, the particles to 
be coated are accelerated inside the wurster tube and fed through the spray cone 
concurrently. 
  As the particles continue travelling upwards, they dry and fall outside the wurster tube 
back towards the base plate. They are guided from the outside back to the inside of the 
tube where they are once again accelerated by the airflow. This produces an extremely 
even film coating. Particles of different sizes are evenly coated. 
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Figure No: 10 
 Globulation 
 Spray drying is the process in which drugs in the form of suspension or solution without 
excipients are sprayed in to a hot stream to produce dry and more spherical particles. This 
process is commonly used for improving the dissolution rates, hence bioavailability of 
poorly soluble drugs. [31]  
  Spray congealing is the process in which a drug is allowed to melt, disperse or dissolve 
in hot melts of gums, waxes or fatty acids and is sprayed in to an air chamber where the 
temperature is kept below the melting point of the formulation components, to produce 
spherical congealed pellets. Both immediate and controlled release pellets can be 
prepared in this process depending on the physiochemical properties of the ingredients 
and other formulation variables. [32] 
Balling or Spherical agglomeration 
 It is the pelletization process in which pellets are formed by a continuous rolling and 
tumbling motion in pans, discs, drums or mixtures.  
 The process consists of conversion of finely divided particles in to spherical particles 
upon the addition of appropriate amounts of liquid.  
 
Liquid induced 
 Liquid is added to the powder before or during the agitation step. As powders come in 
contact with a liquid phase, they form agglomerates or nuclei, which initially are bound 
together by liquid bridges. 
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 These are subsequently replaced by solid bridges, which are derived from the hardening 
binder or any other dissolved material within the liquid phase. The nuclei formed collide 
with other adjacent nuclei and coalesce to form larger nuclei or pellets.  
 
Melt induced 
 It is similar to liquid-induced processes except that the binding material is a melt. 
Therefore, the pellets are formed with the help of congealed material without having to 
go through the formation of solvent-based liquid bridges.[33,34] 
 
Tumbling melt granulation 
 A powdered mixture of meltable and non-meltable materials is fed onto the seeds in a 
fluid-bed granulator. 
 The mixture adheres onto the seeds with the binding forces of a melting solid to form the 
spherical beads.  
 In preparing the spherical beads, both viscosity and particle size of the meltable materials 
should be kept at an optimum value.  
 The particle size of a meltable material should be 1/6 or lower than the diameter of the 
seeds. High-viscosity meltable materials should not be employed to avoid agglomeration 
of seeds and producing beads of low sphericity. [35,36] 
 
Cryopelletization 
 Cryopelletization is a process whereby droplets of a liquid formulation are converted into 
solid spherical particles or pellets by using liquid nitrogen as the fixing medium.  
 The procedure permits instantaneous and uniform freezing of the processed material 
owing to the rapid heat transfer that occurs between the droplets and liquid nitrogen. The 
pellets are dried in conventional freeze dryers. [37,38] 
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2. LITERATURE REVIEW 
 
Kotta Kranthi Kumar et al., designed and evaluated multi particulate system of extended 
release indomethacin capsules USP. By pellatization method: The indometahcin is coated on 
inert sugar spheres by using povidoneK-30 as a binder solutions and Hydroxypropyl 
methylcellose, Ethyl cellose coating agents used for extended release action. The prepared 
capsules were evaluated for content uniformity weight variation, in-vitro disintegration time, 
assay, and in-vitro drug release study. All the formulation exhibited assay, content uniformity 
with in the range given in USP[39]. 
 
S. Eskandari et al., developed an extended release pellet formulation of indomethacin by the 
centrifugation (rotary fluid bed granulation) or powder layering method. Layered, nonpareil 
pellets composed of sugar, Avicel PH 101 and lactose by using FREUND CF granulator and 
were treated by a binder solution (HPC-L) applied by spray gun. The amount of Eudragit NE 30 
D, Opadray and SDS in coating solution adjusts release of the pellets. It would be possible to 
maintain a constant anti-inflammatory serum concentration of indomethacin by ingestion of only 
one unit dose every 12 hours, and reduce the gastrointestinal disturbances [40]. 
 
Kar S K et al., reported controlled release preparations to reduce the gastro irritant and 
ulcerogenic effects of non-steroidal anti-inflammatory drugs. A develop matrix tablet-based 
controlled release formulations of Indomethacin, using ethyl cellulose as the rate-controlling 
polymer. In order to prevent initial release of the drug in the acidic environment of the stomach, 
cellulose acetate phthalate was incorporated in the matrix in varying amounts. The combination 
of cellulose acetate phthalate with ethyl cellulose in the matrix base can be an effective means of 
developing a controlled release formulation of indomethacin with very low initial release 
followed with controlled release up to 14-16 hours [41]. 
 
P.A. Elchidana et al., developed Indomethacin extended release formulation by pelletization 
using the method of extrusion/ spheronization. The drug containing pellets were further coated to 
achieve the required release profile as per USP. Coating systems developed on the principle of 
microporous membrane drug delivery using soluble salt gave the best results [42]. 
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Mircea hirjau et al., produced and characterized pellets containing a non steroidal anti-
inflamatory (NSAID) drug, coated with an entric polymer by extrusion-spheronization using 
microcrystalline cellulose (Avicel PH 101) as a spheronization aid, polyvynilpyrrolidone K30 as 
a binder and lactose as filler. The pellets were analysed for the following physical parameters, 
relevant for subsequent processing of the pellets:size distribution, circularity, bulk density. The 
pellets have shown characteristics suitable for hard capsule filling [43]. 
 
A. Akhgari et al., evaluated the effect of two factors (ratio of Eudaragit S100 and Eudaragit 
L100 and the coating level) on indomethacin release from pellets. Coating formulations were 
designed on the full factorial design. In the ratio of Eudaragit S100: Eudaragit L100 (1:4, 1:1 and 
1:0) and the level of coating (10%, 15%, 20% w/w) respectively. Polymers were coated onto the 
pellets containing 20% (w/w) indomethacin, using a fludized bed coating apparatus. Dissolution 
test was carried out in media with different pH (1.2, 6.5, 6.8 and 7.2). The dissolution data 
revealed that the level of coating and the ratio of polymers are very important to achieve 
optimum formulation [44]. 
 
M. A. Hull et al., suggested the non-steroidal anti-inflammatory drug indomethacin has anti-
colorectal cancer activity. Although indomethacin itself has significant adverse effects, including 
serious upper gastrointestinal toxicity, the development of novel derivatives that may have an 
improved safety profile means that further investigation of the anti-colorectal cancer activity of 
indomethacin is warranted [45]. 
 
Shun Por Li et al., prepared indomethacin pellets by spraying slurry of indomethacin, EudragitB 
5-100, dibutyl sebacate and alcohol onto an appropriate mesh fraction of nonpareil seeds using 
appropriate processing equipment. The average particle diameter and the overall particle size 
distribution of the indornethacin powder were found to be critical factors influencing the 
physical properties of the pellets. Micronized indomethacin powder, having an average particle 
diameter of four microns and a particle size distribution ranging from one to thirteen microns, 
was found to be the optimum for this layering process. The layering process was found to greatly 
affect the release characteristics of the drug from the beadlets [46]. 
 
Shan-Yang Lin et al., estimated the influence of ethyl cellulose (EC) with different viscosity 
grades on in vitro drug release from EC matrix tablets containing Indomethacin. Four viscosity 
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grades of EC (7, 10, 50 and 100 cp) were used. The drug release from Indomethacin tablets 
marginally increased with an increase in viscosity grade. The viscosity grade effect on release 
rates would be differences in tablet porosity [47]. 
 
A. Mesnukul et al., studied the carrier system could effectively enhance the solubility of 
indomethacin and an addition of xanthan gum could sustain the drug release. Eudragit L100 film 
coating could protect the carrier not to be disturbed with HCL buffer pH 1.2 and could dissolve 
in phosphate buffer pH 6.2, therefore, the drug release from coated tablet was initially very low 
but subsequently gradually released and prolonged in phosphate buffer pH 6.2[48]. 
 
H. Lippold et al., developed guaiphenesin pellets are coated in a fluidized bed with aqueous 
ethyl cellulose dispersions (Aquacoat ECD-30) containing different amounts of dibutyl sebacate 
(DBS) as plasticizer. Optimal film formation and zero-order release rates are obtained if the 
produced microcapsules (MC) are treated with heat about 10°C above the minimum film forming 
temperature (MFT). At 25oC of the release medium the coats of the MC with a MFT of 40-50oC 
are in the glassy state, thus the permeability is extremely low [49]. 
 
Andrei Dashevsky et al., prepared a rupturable, capsule-based pulsatile drug delivery system 
with pH-independent properties by using aqueous coating. The drug release is induced by 
rupturing of the top-coating, resulting by expanding of swellable layer upon water penetration 
through the top-coating. A higher coating level was required, when aqueous dispersion was used, 
compared to organic coatings. However, an advantageous aspect of the aqueous coating was the 
lower sensitivity of the lag time to a deviation in the coating level [50]. 
. 
P. B. Deasy et al., developed two new pelletized formulations of indomethacin and compared 
against pellets from the proprietary product, Indocid-R. Extensive dissolution testing involving 
pH-shift and topographical profiling showed that the new product containing polyvinyl 
pyrrolidone had slightly faster in vitro release than the commercial product, but the other new 
product containing sodium lauryl sulphate had reduced drug release. However, on in vivo testing 
in dogs, the new product containing sodium lauryl sulphate had the highest bioavailability of the 
three preparations examined due to its effect as a penetration enhancer [51]. 
 
Mundada .AS et al., investigated for sustaining the drug release from pellet by using Diclofenac sodium (10% 
w/w) as a model drug by extrusion and speronization. The drug containing pellets were coated using DB 
26 
 
plasticized film-coating solutions. Films prepared from novel biomaterial with 20% and 30% w/w 
plasticizer concentration [52]. 
 
Nantharat Pearnchob et al., studied the film forming ability of ethylcellulose powder and the 
effect of formulation factors (plasticizer type and concentration) and curing conditions (curing 
temperature and time). Although ethylcellulose-coated pellets had an uneven surface, extended 
drug release could be obtained with coating level of 15%. Because of its high glass transition 
temperature, ethylcellulose-coated pellets showed unchanged drug release profiles upon storage 
at room temperature for 3 years [53].  
 
 M. Anand Kumar et al., formulated Tamsulosin Hcl extended release pellets using a 
combination of ethyl cellulose N-50 and Eudragit L-100 as a coating material. Initially trials 
were done to optimize the drug loading on to sugar pellets for its uniformity of size and Assay, 
varying the concentration of HPMC E-5 as binder, Aerosil as lubricant and sodium starch 
glycollate as disintegrant. The release study at 2, 3, 5 and 8 hours were the target responses and 
were restricted to 13-34%, 47-68%, NLT 70%, NLT 80% respectively. The optimal coating 
formulation was achieved with Eudragit L-100 9% of the weight of the drug loaded pellets and 
ethyl cellulose N-50 with 25% of the Eudragit L-100 content. The drug release from the 
optimized pellets was compared with the Innovator product FLOMAX capsule showed the 
similarity factor (F2) of 76.43[54]. 
 
KHAN M. S et al., prepard and evaluated microporous pellets loaded with Indapamide (IP) 
using blend of Avicel PH 101 (Microcrystalline cellulose) and sodium chloride (Nacl) by 
extrusion/ spheronization technique for controlled release. Solid, discrete, reproducible pellets 
were obtained. Sieve analysis data indicated that the size of prepared pellets were in the range of 
1135µm to 1245µm. Prepared pellets were spherical in shape, have dent surfaces with pores on 
the surface, as evidenced by scanning electron microscopy (SEM). The optimized formulation F3 
showed 91.41 % drug release up to 24 hours. The stability studies showed no significant 
difference in drug content. The drug release performance was greatly affected by the polymer 
and pore forming agent used in preparation of pellets [55]. 
 
Nisar-Ur-Rahman et al., developed controlled release diltiazem pellets with Eudrgit NE40 and 
the effects of percent drug layering, pH and stirring speed of dissolution media on drug release 
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were also evaluated. The release profile of coated pellets was found to be inversely proportional 
to the thickness of the polymer coat and desirable controlled release characteristics could be 
achieved by manipulating the coating levels. The percent drug layering onto inert pellets had no 
effect on the release rate of coated pellets. Moreover, diltiazem HCL release was fairly 
independent of pH [56]. 
S. Muschert et al., to elucidated the drug release mechanisms in pellets coated with aqueous 
ethyl cellulose dispersion, providing long term stable drug release profiles and containing 
different types of starter cores. DiltiazemHCl release from pellets coated with ethyl cellulose 
containing small amounts of poly(vinyl alcohol)-poly(ethylene glycol) graft copolymer is 
primarily controlled by drug diffusion through the intact polymeric membranes[57]. 
Mustafa Sinan Kaynak et al., formulated of controlled release Glipizide incorporated into non-
pareil seeds by spraying glipizide in a solution in methylene chloride containing polyvinyl 
pyrolidone (PVP 30K) as a binder and talc as anti sticking agent Upper layer coating was 
Eudragit RS 100 PM and Eudragit RL 100 PM polymers were used which provide the release of 
the active ingredients independent of pH of the environment. The amount of the coating solution 
is inreased, the release of glipizide was significantly prolonged. The dissolution profiles of the 
manufactured pellets were evaluated in pH 7.4 phosphate buffer solution in USP apparatus [58]. 
Rakhee A. Surana et al., formulated Phenyl propanolamine hydrochloride sustained release 
pellets. Uni Glatt fluid bed processor (Glatt, Germany) was used for drug solution layering and 
also for sustained release coating. By using hypromellose E5, ethylcellulose 10cps and 
ethylcellulose 45cps polymers in combination. Polymeric solution was prepared by dissolving 
polymers into different solvents in different proportion to form clear coating solution. The pellets 
were evaluated for appearance, shape and size analysis, density, assay, content uniformity, in-
vitro drug release studies, stability study and kinetic study. The optimized batches were charged 
for stability at 40°C and 75% RH for 2 months. The drug release studies were repeated after 
storage for 2 months at conditions like room temperature (RT) and 40ºC and 75% RH [59].  
N. A. Muhammad et al., studied the release of a water soluble drug in various dissolution media 
from pellets coated with HPMCP 50 with 30% plasticizer containing various levels of hydroxyl 
propylcellulose (HPC) or HydroxyPropyl- MethylCellulose (HPMC), HPMCP 50 alone without 
a plasticizer does not form a film. Drug release from coated pellets was found to be ІІ50. Drug 
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release was increased as the percentage of HPC was increased. Higher release rates were 
obtained with HPMC compared to HPC. Coating level significantly influenced drug release in 
0.06 N HCL; however, less of an effect was observed at pH 5.5 [60]. 
P. K. Lakshmi et al., formulated Duloxetine hydrochloride enteric coated pellets using fluidized 
bed. Three separate layers, the drug layer, the barrier layer and the enteric layer were coated onto 
the inert core pellets. Various other properties such as surface morphology, bulk and tapped 
density, hausner´s ratio, yield of pellets, moisture content and particle size distribution were also 
studied in the optimized pellets [61].  
D. Yadav et al., developed and evaluated time dependent rupturable multiparticulate pulsatile 
delivery system for glipizide. Microcrystalline cellulose (MCC) based pellets containing 
glipizied were prepared by extrusion-spheronization technique (Type 1 pellets) coated with two 
consecutive layers, a swellable layer of hydroxyl- propylmethyl cellulose (HPMC) and a 
rupturable layer of plasticized ethylcellulose (EC) with fluidized bed coating. Drug release and 
water uptake studies were carried out on formulated pellets [62].  
A. Kramar et al., evaluated three formulation parameters for the application of polymethacrylic 
films from aqueous dispersions in order to obtain multiparticulate sustained release of diclofenac 
sodium. In this film coating of pellet cores was performed in a laboratory fluid bed apparatus. To 
influenced on plasticizer concentration on the drug release from the pellets [63].  
S. K. Singh et al., developed delayed release micropellet dosage form for Lansoprazole. Drug-
Excipient compatibility data and prototype formulations, the formula that found to be giving the 
desired drug release pattern was considered as the optimized formulation showed delayed release 
profile and it was within the USP limits, and also this formulation done by FBC process which is 
a sophisticated method[64]. 
M. Korber et al., evaluated strategies to set-off the very strong pH-dependent solubility 
(solubility: 80 mg/ml at pH 2 and 0.02 mg/ml at pH 7.5, factor 4000) of a mesylate salt of 
weakly basic model drug (pKa 6.5), in order to obtain pH-independent extended drug release. 
The incorporation of an enteric polymer layer underneath the EC/HPC coating decreased the free 
base formation at pH 7.5 and thus resulted in a more complete release of up to 90% of the drug 
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loading over 18 hours. The release enhancing effect was attributed to an extended acidification 
through the enteric polymer layer [65]. 
F. Siepmann et al., used blends of aqueous dispersions of a water-insoluble and an enteric 
polymer, namely ethylcellulose : hydroxypropyl methylcellulose acetate succinate 
(EC:HPMCAS) and ethyl cellulose:methacrylic acid ethyl acrylate copolymer (EC:EudragitRL), 
as coating materials to control theophylline release from matrix pellets. Varying the polymer 
blend ratio, broad ranges of drug release patterns were obtained at low as well as at high pH. The 
release profiles were rather similar for both types of blends in 0.1 M HCl, where as significant 
differences were observed in phosphate buffer pH 7.4 and the drug release at high pH was much 
slower for EC:HPMCAS blends compared to EC:EudragitRL blends, although HPMCAS 
leached out more rapidly (and to a higher extent) from the film coatings than EudragitRL. The 
EC structures remaining upon HPMCAS leaching are mechanically stronger and drug release is 
controlled by diffusion through the polymeric remnants[66]. 
G.J. Vergote et al., developed controlled release pellet formulation using a nanocrystal colloidal 
dispersion of ketoprofen process the aqueous nanocrystal colloidal dispersion into a hydrophobic 
solid dosage form a spray drying procedure was used. The in vitro dissolution profiles of wax 
based pellets loaded with nanocrystalline ketoprofen are compared with the profiles of wax 
based pellets loaded with microcrystalline ketoprofen and of a commercial sustained release 
ketoprofen formulation. The surfactants used to increase the dissolution rate were either added 
during the production process of the nanocrystal colloidal dispersion (sodium laurylsulphate) or 
during the pellet manufacturing process (Cremophor RH40) [67]. 
J. J. Sousa et al., studied the different ways in which water can be considered an active excipient 
in terms of the amount used to obtain the wet mass, the dispersion within the mass and the drying 
process. Physical characteristics of the pellets were analyzed for pellets within the same fraction 
size of 1-1.4 mm diameter. The analysis indicated that the amount of water and the extrusion and 
drying processes are of great importance and influenced the physical characteristics of the 
resultant pellets. Hence, water should be considered as an 'active' excipient rather than an inert 
component of the extrusion masses [68]. 
S. Muschert et al., studied the drug release mechanisms from aqueous ethylcellulose-coated 
pellets containing different types of drugs and starter cores. Theophylline, paracetamol, 
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metoprolol succinate, diltiazem HCL and metoprolol tartrate were used as model drugs 
exhibiting significantly different solubilities (e.g. 14, 19, 284, 662 and 800 mg/ml at 37 °C in 0.1 
N HCL). Drug release was found to be controlled by diffusion through the intact polymeric 
membranes, irrespective of the drug solubility and type of core formulation. The ethylcellulose 
coating was dominant for the control of drug release, minimizing potential effects of the type of 
pellet core and nature of the surrounding bulk fluid, e.g. osmolality. Thus, this type of controlled 
drug delivery system can be used for very different drugs and is robust [69]. 
N. Vyas et al., to developed ER formulations of a practically insoluble macrolide antibiotics 
clarithromycin suitable for once-a-day oral administration. The polymers carbopol 71G, low-
viscosity (LV) hypromellose, polyox 750N, hypromellose K4M as well as LV-ethylcellulose 
(EC) interspersed with pore-formers like Klucel LF and LV hypromellose. The formulation 
comprised of drug granulated and tableted with commonly employed tableting aids like MCC, 
talc, lactose, colloidal silicon dioxide and magnesium stearate [70]. 
Sandhiya. K. M et al., formulated the oral sustained release matrix tablets of Ambroxol HCl in 
order to improve efficacy, reduce the frequency of administration and better patient compliance. 
Differential scanning calorimetric analysis confirmed the absence of any drug polymer 
interaction. Matrix tablets of Ambroxol Hydrochloride were formulated employing hydrophilic 
polymers HPMC K100M, Carbopol 934P and hydrophobic polymer Ethyl cellulose as release 
retardant polymers. Matrix tablet containing Ethyl cellulose (F7) formulation were found to 
show good initial release 24.24% at 2 hrs and at the end of 12 hrs the drug release was found to 
be 96.86%. The n value for F7 obtained from Korsmeyer-peppas model confirmed that the drug 
release was anomalous diffusion mechanism [71]. 
Siddaramaiahb et al., developed Theophylline by the pelletization technique using the 
extrusion/spheronization method. The drug-containing pellets were further coated to achieve the 
required release profile. The different polymeric coatings of ethyl cellulose (EC), hydroxy propyl 
methyl cellulose (HPMC) and Eudragit S-100 were used. From that coated pellets were 
characterized with regard to the percentage yield, density, friability, sphericity, drug entrapment 
efficiency and size distribution. Coated drug pellets were further characterized by Fourier 
transform infrared (FTIR) spectroscopy. Drug release profiles were studied for uncoated pellets, 
pellets coated with plain polymer and pellets coated with polymeric containing the pore-forming 
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agent, SLS. The in vitro drug release revealed that formulation B4 had the expected release 
profile (24 hrs releases). The optimized formulation is an ideal formulation for once-a-day 
administration [72]. 
George Reyes et al., investigated the application of an aqueous ethylcellulose dispersion 
(Surelease) as a wet granulation agent (release retardant binder), on the release of theophylline 
from extended release (ER) inert matrix tablets. The influence of varying polymer concentration, 
filler choice and compression force on drug release profiles were studied [73]. 
H. Kranz et al., identified an efficient tool to adjust drug release patterns from aqueous and 
organic ethylcellulose (a gastrointestinal insoluble polymer) coated pellets and to evaluate the 
long term stability of the film coatings. The drug release rates from organic coated ethylcellulose 
: Kollicoat MAE 100 P pellets stored at ambient and stress conditions did not change which 
could be explained by differences in the film formation process. The addition of methacrylic 
acid/ethyl acrylate copolymer to ethylcellulose film coatings in combination with an organic 
coating process is able to achieve broad ranges of drug release patterns and to overcome storage 
instability [74]. 
Raghavendra rao N. G et al., developed of rapidly disintegrating oral tablets by direct 
compression using co-grinding and solid dispersion methods by using chlorthalidone as a model 
drug. The solid dispersions and co-grinding method were followed to increase solubility and 
bioavailability. The tablet formulation containing polyvinyl pyrrolidone K-12 solid dispersion 
showed maximum drug release than the chlorthalidone polyvinyl pyrrolidone K-12 co-grinding 
method. Solid dispersion of the drug with the hydrophilic carrier poly vinyl pyrrolidone can 
enhance the dissolution rate of chlorthalidone tablets [75]. 
P. Subhash Chandra Bose et al., prepared floating tablets of diltiazem HCl using xanthan gum 
as carrier by direct compression technique using PVP K-30 as a binder and sodium bicarbonate 
for development of CO2 [76]. 
Fars K. Alanazi et al., prepared albendazole microparticles with hydrophilic polymers such 
ashydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and polyvinyl pyrrolidone 
(PVP) using spray drying technique. The highest dissolution of ABZ was obtained with HPMC 
in 1:1 ratio and with both PVA and PVP in ratio of    1: 4 microparticles. The transformation of 
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ABZ from crystalline to amorphous state by spray drying and the hydrophilic coating of drug 
particles by the polymers are considered among the factors which contributed in improvement of 
ABZ dissolution[77]. 
Chowdary K. P. R et al., evaluated starch phosphate a new modified starch, PVP K-30 and PEG 
4000 as carriers in solid dispersions for enhancing the dissolution rate and efficiency of 
etoricoxib, a BCS class II drug. Hence addition of PVP and PEG 4000 to the solid dispersions in 
starch phosphate is recommended to enhance the dissolution rate of etoricoxib, a BCS class II 
drug [78]. 
G. Ashwini Kumar et al., developed a modified release capsules of mebeverine hydrochloride 
which are designed to controlled release action. Modified release capsules of mebeverine 
hydrochloride were formulated by using the pelletization process by drug layering on inert sugar 
pellets by using PVPK-30 as binder. The drug layered pellets were coated by using the Eudragit 
L-100 and P.E.G-6000 as a first coating material by using I.P.A and water as solvents. The 
coated pellets were again coated by using the Ethyl cellulose N-50, P.E.G-6000, I.P.A and water 
as coating material to sustain the drug release. The coated pellets size and shape is observed 
during processing. The coated pellets is filled in capsules No.2 and these capsules was evaluated 
for assay, weight variation, content uniformity, lock length, moisture content, disintegration and 
in-vitro dissolution tests and these was with in the range. There is no physicochemical interaction 
between drug and excipients and the compatibility study is carried out for four weeks at different 
temperature conditions. The coating step is divided into two steps for getting the desired release 
rate [79]. 
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3. AIM OF WORK 
 
               Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) commonly used for 
the reduction of pain and inflammation caused by condition such as osteoarthritis, gout, 
ulcerative colitis, colon cancer. Its biological half-life is 4.5 hrs. 
 
              When given conventionally it gets released in the upper GIT there by causing irritation 
and ulcer in the upper GIT. The dosage form should be designed in such a way that it should 
minimize or prevent drug release in the acidic environment of upper GIT and start releasing the 
drug in a controlled manner once it reaches the alkaline environment of small intestine. 
 
              Aim of the present work is to formulate the indomethacin pellets to present it in the 
form of capsules (Extended release pellets).To develop and over an extended period of time in 
the gastro intestinal track and compared the in-vitro dissolution profile with that of the marketed 
product. 
 
OBJECTIVES: 
 Reduced frequency of dosage form 
 Improved patient compliance 
 Maximizing bio availability with a minimum dose  
 To study the release profile of the formulation using various polymer  
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4. PLAN OF WORK 
The present approach was made to formulate the Indomethacin extended release pellets 
and evaluation. 
The stages involved in the plan of work are as follows: 
1. Preformulation studies of drug 
        a. Raw material analysis of indomethacin 
        b. Drug-Excipient compatibility study 
        c. Physical observation 
        d. Construction of calibration curve by UV spectrophotometer 
        e. FTIR study 
        f. Particle size analysis 
2. Formulation of extended release pellets 
 Drug layering 
 Extended release coating 
3. Evaluation of pellets 
 Bulk density 
 Tap density 
 Compressibility index (Carr’s index) 
 Hausner ratio 
 Content uniformity 
 Weight variation 
 Percentage yield 
 Capsule lock length 
 LOD (Loss on drying) of the pellets 
 In vitro drug release 
 Investigation of drug release kinetics 
 Comparative in vitro drug release studies with market sample 
 Stability study for selected formulation 
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5. LIST OF MATERIALS AND EQUIPMENTS 
 
Table No.1: List of materials used 
 
                                                     
                
  S. NO              MATERIALS 
                   NAME OF THE 
                      COMPANY 
      1 Indomethacin Fabbrica Italiana Sintetici, Italy.  
      2 Ethyl  cellulose (4cps) Colorcone Asia Ltd, Mumbai. 
      3 Sodium lauryl sulfate Cognis, Germany.        
      4 Hydroxy propyl cellulose Hercules, China. 
      5 Povidone-K30 Zhangzhou Huafu Chemicals co.,Ltd.  
China. 
      6 Low substituted Hydroxy propyl 
Cellulose 
Herculus, China. 
      7 Talc Luzenac Val Chisone, Italy. 
      8 Sugar spheres(500-600µm) Wemer-GmbH.co.KG, Germany. 
      9 Isopropyl alcohol Merck (HPLC grade), Mumbai. 
     10 Empty Hard Gelatin 
Capsule Shell 
Associated capsules Pvt.Ltd., Mumbai. 
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Table No.2: List of equipments used 
   S.NO            MATERIALS 
            NAME OF THE 
               COMPANY 
     1 Glatt particle coater 
granulator(GPCG1.1) 
Pam glatt, Mumbai. 
     2                Dissolution test apparatus Electrolab, Mumbai, India. 
     3 Single pan electronic digital  
Balance 
Mettler Toledo, Switzerland. 
     4 Tap density apparatus Electrolab  ETD-1020, Mumbai,  
India. 
     5 Sieves Gotsons. 
     6 pH meter Mettler Toledo, Switzerland. 
     7      UV-Visible 
 Spectrophotometer 
(UV pharma spec 1700) 
Shimadzu-corporation, U.S.A. 
     8 Vernier calipers Mitutoyo corp. Japan. 
     9 Mechanical stirrer REMI motors Ltd, Maharashtra. 
    10 Automatic capsule filling  
Machine 
Zhejiangn Fuchang machinery 
co.,Ltd. China. 
    11 Peristalic pump Pam glatt, Mumbai. 
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6. DRUG & POLYMER PROFILE 
6.1 Drug Profile 
Indomethacin[80,81,82,83] 
 
Structural formula 
Chemical name 1-(4-Chorobenzoyl)-5-methoxy-2-methyl- 
1H-indole-3-acetic acid 
Molecular formula C19H16CINO4 
CAS No. 53-86-1 
Molecular weight 357.8 
Melting point 158-162°C 
Functional categories An anti-inflamatory, analgesic  agent 
Description A white to yellow-tan powder 
Solubility Practically insoluble in water, soluble 1 in  
50 of ethanol, 1in 30 of chloroform, and 1  
in about 40 of ether, soluble in acetone 
Standards Indomethacin contains not less than 98.0 
per cent and not more than 101.0 per cent 
of C19H16CINO4, calculated with reference 
to the dried substances  
Storage Store in well-closed, light-resistant containers 
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Indication:- 
        Clinical indications for indomethacin include 
 
 Rheumatoid arthritis 
 Ankylosing arthritis 
 Arthritic gout 
 Osteoarthritis 
 Juvenile arthritis 
 Psoriatic arthritis 
 Reactive arthritis 
 Colonic cancer 
 Inflammatory bowel disease 
 
Mechanism of action: 
Indomethacin is a non-selective inhibitor of cyclo-oxygenase (COX) 1 and 2, enzymes that 
participate in prostaglandin synthesis from arachidonic acid. Prostaglandins are hormone-like 
molecules normally found in the body, where they have a wide variety of effects, some of which lead 
to pain, fever, and inflammation. Prostaglandins also cause uterine contractions in pregnant women. 
Indomethacin is an effective tocolytic agent, able to delay premature labour by reducing uterine 
contractions through inhibition of PG synthesis in the uterus and possibly through calcium channel 
blockade. 
 
Indomethacin has two additional modes of actions with clinical importance: 
     It inhibits motility of polymorphonuclear leukocytes, similar to colchicines 
 It uncouples oxidative phosphorylation in cartilaginous mitochondria, like salicylates 
These additional effects account as well for the analgesic and anti-inflammatory properties. 
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Pharmacokinetics 
Indomethacin is rapidly and almost completely absorbed from the gastrointestinal tract after 
oral ingestion. The peak concentration in plasma is attained with in 2 hrs in the fasting subject but 
may be somewhat delayed when the drug is taken after meals. The concentration in plasma required 
for an anti-inflammatory effect have not been definitely determined but probably less than 1µg/ml. 
Indomethacin is 90% bound to plasma proteins and also extensively bound to tissues. 
Indomethacin is subject to considerable enterohepatic circulation. Metabolic reaction include 
O-demethylation, N-deacetylation, and glucuronic acid conjugation, the major metabolites being 
desmethyl Indomethacin (DMI), and desmethyldeschlorbenzoy Indomethacin (DMBI) and their 
glucuronides. These substances, together with unchanged indomethacin and its glucuronide, are 
excreted in both the urine (up to about 60% of the dose in 48 h) and the feces (up to about 30% of 
the dose in 96 hrs) in variable amount. Expressed as a percentage of the dose, the average amounts 
excreted in the urine in 48 hrs are: unchanged Indomethacin 5 to 20% (dependent on urinary pH), 
Indomethacin glucuronide 6 to 26%, DMI and its glucuronide 8 to 23%, DBI and its glucuronide 4 
to 20%, DMBI and its glucuronide less than 3%, in the feces the major metabolites found are DMBI 
(up to about 16%) and DMI (up to about 12%), with only small amont of unchanged Indomethacin 
and DBI. 
Adverse effects 
Since Indomethacin inhibits both COX-1 and COX-2, it inhibits the production of 
prostaglandins in the stomach and intestine which maintain the mucous lining of the gastrointestinal 
tract. Indomethacin, therefore, like other non-selective COX inhibitors, can cause peptic ulcers. The 
ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. 
Indomethacin also reduces plasma rennin activity and aldosterone levels, and increases sodium and 
potassium retention. It also enhances the effects of vasopressin. Together these may lead to: 
 Edema (swelling due to fluid retention) 
 Hyperkalemia (high potassium levels) 
 Hypernatremia (high sodium levels) 
 Hypertension (high blood pressure) 
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The drug may also cause elevations of serum creatinine and more serious renal damage such 
as acute renal failure, chronic nephritis and nephritic syndrome. These conditions also often being 
with edema and hyperkalemia. Additionally, indomethacin quite often causes headache (10 to 20%), 
sometimes with vertigo and dizziness, hearing loss, tinnitus, blurred vision (with or without retinal 
damage) and worsens Parkinson’s disease, epilepsy, and psychiatric disorders. Cases of life-
threatening shock (including angioedema, sweating, severe hypotension and tachycardia as well as 
acute bronchospasm), sever or lethal hepatitis and severe bone marrow damage have all been 
reported. Skin reactions and photosensitivity are also possible side effects. 
Contraindications 
            
 Concurrent peptic ulcer, or history of ulcer disease 
 Allergy to indomethacin, aspirin, or other NSAIDS 
 Patients with nasal polyps reacting with an angioedema to other NSAIDS 
 Children under 2 years of age (with the exception of neonates with patent ductus 
arteriosus) 
 Severe pre-existing renal and liver damage 
 Caution: preexisting bone marrow damage (frequent blood cell counts are indicated) 
 Caution: bleeding tendencies of unknown origin (indomethacin inhibits platelet 
aggregation) 
 Caution:Parkinson´s disease, epilepsy, psychotic disorders (indomethacin may worsen 
these conditions) 
 
Dose 
             Orally, 50 to 200 mg daily, in divided doses, with food. As suppositories 100 mg at night 
and in the morning if required. Maximum combined oral and rectal dose, 150 to 200 mg daily. 
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6.2 Polymers profile 
6.2.1 Ethyl cellulose [84] 
1. Non proprietary Names: 
 BP         :Ethyl cellulose 
 USPNF : Ethyl cellulose 
2. Synonyms    : Ethocel, Surelease 
    3. Chemical name CAS Registry number: Cellulose ethyl ether [9004-57-3] 
    4. Empirical Formula and Molecular Weight: C12H23O6 
    5. Structural formula: 
 
    6. Description: Ethyl cellulose is a tasteless free flowing white to lighten colored. 
    7. Application in pharmaceutical formulation and technology 
The main use of ethyl cellulose in oral formulations is as a hydrophobic coating agent for 
tablets and granules or pellets. Ethyl cellulose coatings are used to modify the release of a drug, 
or to improve the stability of a formulation. Ethyl cellulose, dissolved in an organic solvent or 
solvent mixture, can be used on its own to produce water-insoluble films. Higher-viscosity 
ethylcellulose grades tend to produce stronger and more durable films. Drug release through 
ethylcellulose coated dosage forms can be controlled by diffusion through the film coating. This 
can be a slow process unless a large surface area (e.g. pellets or granules compared with tablets) 
is utilized. In those instances, aqueous ethyl cellulose dispersions are generally used to coat 
granules or pellets. Ethyl cellulose may additionally be employed as a binder. 
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Various viscosity grades (mPa s)  
Ethocel Std 4 Premium, Ethocel Std 7FP Premium, Ethocel Std 7 Premium Ethocel Std 
10FP Premium, Ethocel Std 10P Premium, Ethocel Std 14 Premium, Ethocel Std 20P Premium, 
Ethocel Std 45P Premium, Ethocel Med 50P Premium, Ethocel Med 70P Premium, Ethocel Std 
100FP Premium, Ethocel Std 100P Premium, Ethocel Std 100P, Ethocel Std 200P Premium, 
Ethocel Std 300P Premium. 
    8. Typical properties:- 
 Density (bulk): 0.4 g/cm3 
 Moisture content: Ethyl cellulose absorbs very little water from humid air or during 
immersion, and that small amount evaporates easily. 
 Glass transition temp:129-133°C 
 Solubility: Practically insoluble in glycerine, propylene glycol and water  
 Viscosity: 7 to 100 cps for 5%w/v aqueous solution at 25°C 
 Melting point: 240-255°C 
9. Stability 
Stable slightly hygroscopic material chemically resistant to alkali both dilute and 
concentrated. Subject to oxidative degradation in the presence of sunlight or UV light at elevated 
temperature. 
 10. Incompatibility 
             Incompatible with paraffin wax and microcrystalline wax. 
 11. Safety 
          Non toxic, non allergic and non irritating. 
6.2.2 Povidone[84] 
1. Nonproprietary Names 
      BP: Povidone 
      JP: Povidone 
43 
 
      USP: Povidone 
2. Synonyms 
Kollidon, Plasdone, poly[1-(2-oxo-1-pyrrolidinyl)ethylene], polyvinylpyrrolidone, PVP, 1-
vinyl-2-pyrrolidinone polymer.         
3. Chemical Name and CAS Registry Number 
      1-Ethenyl-2-pyrrolidinone homopolymer [900l3-39-8] 
4. Empirical Formula and Molecular Weight 
       (C6H9NO)n 2500–3 000 000 
5. Structural Formula 
                                                
6. Functional Category 
Disintegrant, dissolution aid, suspending agent, tablet binder. 
7. Applications in Pharmaceutical Formulation or Technology 
 Although povidone is used in a variety of pharmaceutical formulations, it is primarily 
used in solid-dosage forms. In tableting, povidone solutions are used as binders in 
wetgranulation processes. Povidone is also added to powder blends in the dry form and 
granulated in situ by the addition of water, alcohol, or hydroalcoholic solutions. Povidone is used 
as a solubilizer in oral and parenteral formulations and has been shown to enhance dissolution of 
poorly soluble drugs from solid-dosage forms. Povidone solutions may also be used as coating 
agents. Povidone is additionally used as a suspending, stabilizing, the solubility of a number of 
poorly soluble active drugs may be increased by mixing with povidone. 
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Use Concentration (%) 
Carrier for drugs         10–25 
Dispersing agent        Up to 5 
Eye drops          2–10 
Suspending agent        Up to 5 
Tablet binder, tablet diluent, or 
coating agent 
         0.5–5 
 
         
8. Description 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder. Povidones with K-values equal to or lower than 30 are manufactured by 
spray-drying and occur as spheres. Povidone K-90 and higher K-value povidone are 
manufactured by drum drying and occur as plates. 
 
9 Typical Properties 
           Acidity/alkalinity: pH = 3.0–7.0 (5% w/v aqueous solution). 
           Melting point: softens at 150°C. 
           Moisture content: povidone is very hygroscopic, significant amounts of moisture being 
absorbed at low relative humidities. 
          Solubility: freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration of 
a solution is limited only by the viscosity of the resulting solution, which is a function of the K-
value. 
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           Viscosity (dynamic): the viscosity of aqueous povidone solutions depends on both the 
concentration and the molecular weight of the polymer employed. 
10. Stability and Storage Conditions 
              It is stable to a short cycle of heat exposure around 110–130°C, it should be stored in an 
airtight container in a cool and dry place. 
11. Incompatibilities 
           Povidone is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. It forms molecular adducts in solution with sulfathiazole, 
sodiumsalicylate, salicylicacid, phenobarbital, tannins.  
 
6.2.3 Hydroxypropyl Cellulose, Low-substituted[84] 
 1. Nonproprietary Names 
        JP: Low-substituted hydroxypropylcellulose 
        USPNF: Low-substituted hydroxypropyl cellulose 
2. Synonyms 
        Hyprolose, low-substituted, L-HPC. 
3. Chemical Name and CAS Registry Number 
       Cellulose, 2-hydroxypropyl ether (low-substituted) [78214-41-2] 
4. Empirical Formula and Molecular Weight 
        R is H or [CH2CH(CH3)O]mH 
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5. Structural Formula 
          
 
 
6. Functional Categories 
           Tablet and capsule disintegrant, tablet binder. 
7. Applications in Pharmaceutical Formulation or Technology: 
              Low-substituted hydroxypropyl cellulose is widely used in oral solid-dosage forms. It is 
primarily used in tableting as a disintegrant, and as a binder in wet granulation. In addition, low-
substituted hydroxypropyl cellulose has been used to delay the release of drug from a tablet 
matrix. There are a number of grades that have different particle sizes and substitution levels. 
LH-11 has the medium substitution level and the largest particle size, and is typically used as an 
anti capping agent and disintegrant for direct compression. LH- 21 is used as a binder and 
disintegrant for tablets through the wet-granulation process. LH-31 is a small-particle grade used 
especially for extrusion to produce granules, as it has a small particle size that is better for 
passing a screen. The typical content of low-substituted hydroxypropyl cellulose in a formulation 
is approximately 5–25%. 
8. Description 
            Low-substituted hydroxypropyl cellulose occurs as a white to yellowish white powder or 
granules. It is odorless or has a slight, characteristic odor, and it is tasteless. 
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9. Typical Properties 
           Acidity/alkalinity: pH = 5.0–7.5 for 1% w/v aqueous suspension. 
           Melting point: decomposition at 275oC. 
           Solubility: practically insoluble in ethanol (95%) and in ether, Dissolves in a solution of 
sodium hydroxide (1 in 10) and produces a viscous solution. Insoluble, but swells in water. 
10. Stability and Storage Conditions 
            Low-substituted hydroxypropyl cellulose is a stable, though hygroscopic, material. The 
powder should be stored in a well closed container. 
11. Incompatibilities 
            Alkaline substances may interact. If a tablet formulation contains such a material, its 
disintegration may be extended after storage. 
12. Safety 
           Nontoxic and non irritant material. 
 
6.2.4 Hydroxy propyl cellulose[84] 
1. Nonproprietary Names 
         BP: Hydroxypropylcellulose 
         JP: Hydroxypropylcellulose 
         USPNF: Hydroxypropyl cellulose 
2. Synonyms 
         Cellulose, Hyprolose, Klucel, Methocel, Nisso HPC.  
3. Chemical Name and CAS Registry Number 
         Cellulose, 2-hydroxypropyl ether [9004-64-2] 
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4. Empirical Formula and Molecular Weight 
         Molecular weight has a range of 50 000–1 250 000;  
5. Structural Formula 
         R is H or [CH2CH(CH3)O]mH 
 
 
 
6. Functional Category 
             Coating agent, emulsifying agent, stabilizing agent, suspending agent, tablet binder, 
thickening agent, viscosity-increasing agent. 
7. Applications in Pharmaceutical Formulation or Technology: 
              Hydroxypropyl cellulose is widely used in oral and topical pharmaceutical formulations; 
In oral products, hydroxypropyl cellulose is primarily used in tableting as a binder, film-coating, 
and extended-release matrix former. The release rate of a drug increases with decreasing 
viscosity of hydroxypropyl cellulose. The addition of an anionic surfactant similarly increases 
the viscosity of hydroxypropyl cellulose and hence decreases the release rate of a drug. A low-
substituted hydroxypropyl cellulose is used as a tablet disintegrant, Hydroxypropyl cellulose is 
also used in cosmetics and in food products as an emulsifier and stabilizer. 
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                  Use Concentration (%) 
Extended release-matrix former          15–35 
Tablet binder            2–6 
Tablet film coating              5 
 
8. Description 
             Slightly yellow-colored, odorless and tasteless powder.  
9. Typical Properties 
             Acidity/alkalinity: pH = 5.0–8.5 for a 1%w/v aqueous solution. 
             Density (bulk): 0.5 g/cm3. 
             Melting point: softens at 130°C; chars at 260–275°C. 
             Moisture content:  Typical equilibrium moisture content values at 25°C are 4% w/w at 
50% relative humidity and 12% w/w at 84% relative humidity. 
             Solubility: soluble 1 in 10 parts dichloromethane,1 in 2.5 parts ethanol (95%),1 in 2 Parts 
methanol; 1 in 5 parts propan-2-ol,1 in 5 parts propylene glycol; and 1 in 2 parts water. 
Practically insoluble in aliphatic hydrocarbons, aromatic hydrocarbons, carbon tetrachloride, 
petroleum distillates, glycerin, and oils. 
            Viscosity (dynamic): a wide range of viscosity types are commercially available. 
10. Stability and Storage Conditions 
            Hydroxypropyl cellulose powder is a stable material, although it is hygroscopic after 
drying. Aqueous solutions of hydroxypropyl cellulose are stable at pH 6.0–8.0. 
            Hydroxypropyl cellulose powder should be stored in a well closed container in a cool and 
dry place. 
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11. Incompatibilities 
                Incompatibility with substituted phenol derivatives, such as methylparaben and 
propylparaben. The presence of anionic polymers may increase the viscosity of hydroxypropyl 
cellulose. 
12. Safety 
          Nontoxic and nonirritant material. 
6.2.5 Sodium lauryl sulfate[84] 
1. Nonproprietary Names 
            BP: Sodium lauryl sulfate 
            JP: Sodium lauryl sulfate 
            USPNF: Sodium lauryl sulfate 
2. Synonyms 
           Dodecyl sodium sulfate, sodium dodecyl sulfate, sodium laurilsulfate, sodium 
monododecyl sulfate. 
3. Chemical Name and CAS Registry Number 
           Sulfuric acid monododecyl ester sodium salt [151-21-3] 
4. Empirical Formula and Molecular Weight 
           C12H25NaO4S           Mol.wt :288.38 
5. Structural Formula 
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6. Functional Category 
            Anionic surfactant, detergent, emulsifying agent, skin penetrant, tablet and capsule 
lubricant, wetting agent. 
7. Applications in Pharmaceutical Formulation or Technology 
          Sodium lauryl sulfate is an anionic surfactant employed in a wide range of non parenteral 
pharmaceutical formulations and cosmetics. It is a detergent and wetting agent effective in both 
alkaline and acidic conditions. 
Use Concentration (%):0.5–2.5 
8. Description 
          Sodium lauryl sulfate consists of white or cream to pale yellow colored crystals, flakes, or 
powder having a smooth feel, a soapy, bitter taste, and a faint odor of fatty substances. 
9. Typical Properties 
            Acidity/alkalinity: pH = 7.0–9.5 (1% w/v aqueous solution)  
            Density: 1.07 g/cm3  
            HLB value: 40 
            Melting point: 204–207°C (for pure substance) 
            Moisture content: 45%, sodium lauryl sulfate is not hygroscopic. 
            Solubility: freely soluble in water, giving an opalescent solution, practically insoluble in 
chloroform and ether. 
10. Stability and Storage Conditions 
Sodium lauryl sulfate is stable under normal storage conditions. The bulk material should 
be stored in a well-closed container away from strong oxidizing agents in a cool, dry place. 
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11. Incompatibilities 
 Sodium lauryl sulfate is also incompatible with some alkaloidal salts and precipitates 
with lead and potassium salts. 
12. Safety 
It is a moderately toxic material with acute toxic effects including irritation to the skin, 
eyes, mucous membranes, upper respiratory tract and stomac. 
 
6.2.6 Talc[84] 
1. Nonproprietary Names 
       BP: Purified talc 
       JP: Talc 
       USP: Talc 
2. Synonyms 
        Altalc, Hydrous magnesium calcium silicate, Hydrous magnesium silicate. 
3. Chemical Name and CAS Registry Number 
        Talc [14807-96-6] 
4. Empirical Formula and Molecular Weight 
          Mg6 (Si2O5)4(OH)4.  
   5. Functional Category 
           Anti sticking agent, glidant, tablet and capsule diluent, tablet and capsule lubricant. 
6. Applications in Pharmaceutical Formulation or Technology 
            Talc was once widely used in oral solid dosage formulations as a lubricant and diluent. It 
is widely used as a dissolution retardant in the development of controlled-release products. Talc 
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is also used as a lubricant in tablet formulations and a novel powder coating for extended-release 
pellets and as an adsorbent. 
 Uses of talc: 
 Use Concentration in percentage (%) 
 Dusting powder: 90.0–99.0 
 Glidant and tablet lubricant: 1.0–10.0 
 Tablet and capsule diluent: 5.0–30.0 
7. Description 
               Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft to the touch and free from grittiness. 
8. Typical Properties 
Acidity/alkalinity: pH = 7–10 for a 20% w/v aqueous dispersion. 
Moisture content: talc absorbs insignificant amounts of water at 25°C and relative                
humidities up to about 90%. 
Solubility: practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Specific gravity: 2.7–2.8. 
9. Stability and Storage Conditions 
              Talc is a stable material and may be sterilized by heating at 160°C for not less than 1 
hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. Talc should 
be stored in a well-closed container in a cool, dry place. 
10. Incompatibilities 
              Incompatible with quaternary ammonium compounds. 
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11. Safety 
              Inhalation of talc causes irritation and may cause severe respiratory distress. 
6.2.7 Sugar Spheres[84] 
1. Nonproprietary Names 
         BP: Sugar spheres 
         USPNF: Sugar spheres 
2. Synonyms     
         Non-pareil, non-pareil seeds, sugar seeds, Suglets. 
3. Functional Category 
         Tablet and capsule diluent. 
4. Applications in Pharmaceutical Formulation or Technology 
         Sugar spheres are mainly used as inert cores in capsule and tablet formulations, particularly 
multi particulate sustained release formulations. They form the base upon which a drug is coated, 
usually followed by a release-modifying polymer coating. Alternatively, a drug and matrix 
polymer may be coated onto the cores simultaneously. The active drug is released over an 
extended period either via diffusion through the polymer or through to the controlled erosion of 
the polymer coating. Complex drug mixtures contained within a single-dosage form may be 
prepared by coating the drugs onto different batches of sugar spheres with different protective 
polymer coatings. 
5. Description 
         Sugar spheres as approximately spherical granules of a labeled nominal-size range with a 
uniform diameter and containing not less than 62.5% and not more than 91.5% of sucrose, 
calculated on the dried basis. The remainder is chiefly starch. The diameter of sugar spheres 
varies from 200 to 2000 mm. 
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6. Typical properties 
Density: Particle size distribution: sugar spheres are of a uniform diameter. 30–35 mesh (500–
600 mm) 
Solubility: solubility in water varies according to the sucrose-to starch ratio. The sucrose 
component is freely soluble in water, whereas the starch component is practically insoluble in 
cold water. 
7. Stability and Storage Conditions 
            Sugar spheres are stable when stored in a well-closed container in a cool, dry place 
 
6.2.8 Isopropyl alcohol[84] 
1. Nonproprietary Names 
        BP: Isopropyl alcohol 
        JP: Isopropanol 
        USP: Isopropyl alcohol 
2. Synonyms 
               Dimethyl carbinol; IPA; isopropanol;2-propanol;sec-propyl alcohol. 
3. Chemical Name and CAS Registry Number 
               Propan-2-ol [67-63-0] 
4. Empirical Formula and Molecular Weight 
               C3H8O      Mol.wt: 60.1 
 
 
 
56 
 
5. Structural Formula 
                                         
 
6. Functional Category 
            Disinfectant, solvent. 
7. Applications in Pharmaceutical Formulation or Technology 
Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical formulations 
primarily as a solvent in topical formulations. It is not recommended for oral use owing to its 
toxicity Isopropyl alcohol is also used as a solvent both for tablet film-coating and for tablet 
granulation, therapeutically, isopropyl alcohol has been investigated for the treatment of 
postoperative nausea or vomiting. 
8. Description 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a 
characteristic, spirituous odor resembling that of a mixture of ethanol and acetone; it has a 
slightly bitter taste. 
9. Typical Properties 
      Boiling point: 82.48C 
      Flammability: flammable. 
      Melting point: 88.58C 
      Moisture content: 0.1–13% w/w. 
      Solubility: miscible with benzene, chloroform, ethanol (95%),ether, glycerin, and water. 
Soluble in acetone, insoluble in salt solutions.  
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10. Stability and Storage Conditions 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
11. Incompatibilities 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, which 
cause decomposition.  
.12. Safety 
Isopropyl alcohol is widely used in cosmetics and topical pharmaceutical formulations.  
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7. EXPERIMENTAL INVESTIGATION 
7.1 Preparation of standard curve of Indomethacin[85]: 
The drug in solution with concentration of 50 µg/ml was prepared. Serial dilutions of 5-50 
µg/ml drug concentration were made by using the methanol and phosphate buffer pH 6.2. They 
were analyzed spectrophotometrically by measuring the absorbance at 319 nm wavelength. 
 (a) Preparation of pH 6.2 phosphate buffer [86]: 
Potassium dihydrogen orthophosphate (KH2PO4) 68 gms was taken in 10 liters of purified 
water and 3.24 gms of sodium hydroxide pellets was mixed and adjusted to pH 6.2. 
(b) Calibration curve of Indomethacin in 6.2 pH phosphate buffer: 
Drug (100 mg) was dissolved in 100 ml of methanol from this solution 5 ml was 
withdrawn and diluted to 100 ml with phosphate buffer pH 6.2. From the stock solution serial 
dilution were made to obtain the solution in concentrations ranging from 5-50 µg/ml. They were 
analyzed spectrophotometrically by measuring the absorbance at 319 nm. 
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Table No: 3 Standard calibration curve of Indomethacin at pH 6.2 
                
S. No 
Concentration 
(µg/ml) 
Absorbance 
1 5 0.092 
2 10 0.196 
3 15 0.295 
4 20 0.393 
5 25 0.492 
6 30 0.597 
7 35 0.688 
8 40 0.784 
9 45 0.885 
10 50 0.983 
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Figure No: 11 Standard calibration curve of Indomethacin 
 
 
 
7.2 Preformulation studies [87]: 
Preformulation testing is defined as investigation of physical and chemical properties of 
drug substances alone and when combined with excipients.           
 
7.2.1 Spectroscopic studies [87, 88]: 
               1. UV Spectroscopic Analysis 
               2. IR Spectroscopic Analysis 
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(a) UV spectroscopy (Determination of λ max) 
                The light absorption in the range 200 to 800 nm of a solution buffer it exhibit a 
maximum only at about 319 nm. 
 
(b) Raw material analysis of Indomethacin USP [86]: 
               Raw material analysis of Indomethacin was carried out using Fourier Transform Infra 
red spectrophotometer (FTIR) by KBr pellet method. 
 
7.2.2 Particle size distribution of Indomethacin powders [67]: 
           The particle size measurement of indomethacin micronized powder was determined by 
using a (Mastersizer-2000) particle size analyzer. An appropriate amount of indomethacin 
powder was added into the analyzing chamber containing deionized water as the medium. A few 
drops of Triton solution (1% w/w) were added to disperse the powders. Test results of the type of 
powder were recorded. In addition, this powder was examined under a microscope with a 
magnification of 400X.  
 
7.2.3 Compatibility studies of Indomethacin and formulation components: 
              The compatibility of drug and polymers under experimental conditions is important 
prerequisite before formulation. It is therefore necessary to confirm that the drug does not react 
with the polymers and excipients under experimental conditions and not affecting the shelf life of 
product or any other unwanted effects on the formulation. The physical mixture of drug & 
polymers were used for determination of Infrared spectrums.  
 
7.2.4 Physical observation [54, 79]: 
             The active ingredients were mixed well with all excipients in binary ratio and small 
portion of this mixed powder was placed in cleaned and dried vial in stability chamber at 25°C/ 
60% RH & 40°C/ 75% RH. Physical observation has been carried out visually for 0, 2 and 4 
weeks. 
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7.3 Formulation development: 
                  Study involves formulation of an extended release Indomethacin drug loaded pellets, 
release over an extended period of time. 
 
Selection of Process 
     Pellets were done by Fluid bed processor (FBP). 
     General procedure for formulation of extended release pellets: 
     Preparation of drug layering solution: 
 Required quantity of isopropyl alcohol was taken into a suitable vessel and to it ethyl 
cellulose 4cps added and stirred well to get clear solution. This process was done at room 
temperature.  
 To the above solution purified water, sodium lauryl sulfate and hydroxy propylcellulose 
were added slowly under continuous stirring to dissolve completely.  
 Then Indomethacin was added slowly under continuous stirring to get a uniform 
dispersion. After attaining uniform dispersion talc was added immediately with 
continuous stirring for not less than 30 min. 
 The above dispersion was passed through #40 sieve and complete dispersion was passed. 
 Dispensed sugar spheres were loaded into wurster column and the process started with 
present parameters to adjust the fluidization. 
 The dispersion was sprayed onto sugar spheres at inlet temperature of 40±5°C and bed 
temperature of 35 ±5°C then spray rate increased slowly to optimum rate. 
 The drug layered pellets was dried for not less than 15 min with low fludization at a bed 
temperature of 40±5°C and weight gain was checked. 
 The drug layered pellets were passed initially through #20 sieve and the twins retained on 
the sieve were removed. Again they are passed through #30 sieve and the passed drug 
layered pellets were discarded. 
 The pellets were stored in suitable air tight container. 
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Extended release coating: 
 Extended release coating solution in which polymer concentration 1:1 ratio was prepared 
(5%, 7% and 9%) weight build up was noted. 
 Required quantity of isopropyl alcohol was transferred into a suitable vessel at room 
temperature to that ethyl cellulose 4 cps, purified water, hydroxypropyl cellulose was 
added slowly under continuous stirring until it dissolves completely. 
 The drug layered pellets were loaded into wurster column and the process started with 
present parameters to adjust the fluidization. 
 The solution was sprayed onto drug layered pellets at inlet temperature of 40±5°C and 
bed temperature of 35±5°C then spray rate increased slowly to optimum rate. 
 The extended release coated pellets was dried for not less than 30 min with low 
fluidization at a bed temperature of 40±5°C and weight build up was checked 
 The extended release coated pellets were passed initially through #20 sieve and the twins 
retained on the sieve were removed. Again they are passed through #30 sieve and the 
passed drug layered pellets were discarded. 
 
Lubrication 
 The talc was passed through #40 sieve and pellets were lubricated. 
7.3.1 Parameters in capsule: 
Table No: 4 
Capsule shells Green opaque cap/clear transparent body size 1 empty hard 
gelatin capsule shell imprinted with X08 on both cap and 
body with black ink. 
Description    Green opaque cap/clear transparent body size 1 hard gelatin 
capsule shells filled with pale yellow pellets & imprinted 
with X08 on both cap and body with black ink. 
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7.3.2 Parameters maintained in fluid bed processor: 
Table No: 5 
Machine type Pam Glatt 1.1  
Material nozzle diameter 0.8 mm 
Number of guns 01 
Spray mode  Continuous  
Inlet air temperature 50±10°C 
Product temperature 40±5°C 
Exhaust temperature 40±5°C 
Atomization  2-3 bar 
Air flow 600 -750 m/sec 
Drive speed 55-65% 
Peristaltic pump  speed 08-12 rpm 
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Table:6: 7.3.3 Formulation chart of Indomethacin pellets: 
   Drug layering 
 
 
 
 
 
\ 
\ 
S. 
No 
Ingredients 
Quantity per unit (mg) 
F-1 F-2 F-3 F-4 F-5 F-6 
1 Indomethacin 75 75 75 75 75 75 
2 Ethyl cellulose (4cps) 5 5 5 7 5 5 
3 Povidone K30 20 - - - - - 
4 Hydroxypropyl Cellulose, 
Low-substituted 
- 20 - - - - 
5 Hydroxypropyl Cellulose - - 20 18 20 20 
6 Sodium lauryl sulfate 0.5 0.5 0.5 0.5 0.5 0.5 
7 Talc 1 1 1 1 1 1 
8 Sugar spheres (500-600 µm) 217.5 217.5 217.5 217.5 217.5 217.5 
9 Isopropyl alcohol q.s q.s q.s q.s q.s q.s 
10 Purified water q.s q.s q.s q.s q.s q.s 
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 Extended release coating 
 
S. No Ingredients 
Quantity per unit (mg) 
F-1 F-2 F-3 F-4 F-5 F-6 
     11 Ethyl cellulose 
(4cps) 
8 8 8 8 11 14 
12 Povidone K30 8 - - - - - 
13 Hydroxypropyl 
Cellulose, Low-
substituted 
- 8 - - - - 
14 Hydroxypropyl 
Cellulose 
- - 8 8 11 14 
15 Sodium lauryl 
sulfate 
1 1 1 1 1 1 
16 Isopropyl alcohol q.s q.s q.s q.s q.s q.s 
17 Purified water q.s q.s q.s q.s q.s q.s 
 Extended release 
pellet weight 
336 336 336 336 342 348 
18 Talc 1 1 1 1 1 1 
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7.4 Evaluation of prepared pellets: [89] 
7.4.1 (i) Bulk density: 
Weighed quantity of 60 gms pellets was transferred into a 100 ml measuring cylinder 
without tapping, during transfer the volume occupied by pellets was measured. Bulk density was 
measured by using formula. 
                                                          Pi = m/Vo   
   Where, 
             Pi = Bulk density 
             m = Mass of the pellets,  
             Vo = Untapped Volume 
 
7.4.1 (ii) Tapped Density: 
Weighed quantity of 60 gms pellets was taken into graduated cylinder, volume occupied 
by granules was noted down. Then cylinder was subjected to 500 taps in tapped density tester 
(Electro Lab USP II), the % Volume variation was calculated by following formula. 
                                          Pt = m/Vi 
Where, 
            Pt = Tapped density 
            m= Mass of the pellets,  
            Vi = Tapped volume 
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7.4.2 Carr’s compressibility index: 
Compressibility is the ability of pellets to decrease in volume under pressure. Using 
untapped density and tapped density the percentage compressibility of pellets were determined, 
which is given as Carr’s compressibility index. 
                                            
                               CI=Vi-Vo / Vi × 100 
Where,  
 CI   = Compressibility index             
 Vo  = Bulk density  
 Vi
 
  = Tapped density    
                               
 
Table No: 7 Compressibility index 
                   
                                         
                                  
  
 
 
 
 
 
Compressibility index (%) Flow characters 
<   10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
> 32 Very poor 
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7.4.3 Hausner´s ratio 
It is measurement of frictional resistance of the drug. It was determined by the ratio of 
tapped density and bulk density. 
  
    Hausner´s ratio = Vo/Vi 
Where,  
             Vo = Bulk density  
  Vi  = Tapped density  
 
Table No: 8 Hausner´s ratio 
              
 
 
 
 
 
 
 
 
 
 
 
Flow characters Hausner´s  ratio 
Excellent 1.11 
Good 1.12 – 1.18 
Fair 1.19 – 1.25 
Passable 1.26 – 1.34 
Poor 1.35 – 1.45 
Very poor 1.46 – 1.59 
Very very poor >1.60 
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7.4.4 Procedure for content uniformity: [86] 
             The content of one capsule was transferred into 200 ml volumetric flask, to it 100 ml 
equal volume of methanol and phosphate buffer (pH 6.2) was added. Then the solution was 
sonicated until then contents are dispersed and volume was made up with methanol and 
phosphate buffer (pH 6.2) in 1:1 ratio. This solution contains about 25 µg/ml indomethacin. 
Concomitantly the absorbance was determined 319 nm, in spectrophotometer, using the 
methanol and pH 6.2 phosphate buffer mixture as the blank. 
       By calculating the formula:  
                                                (TC/D)(AU/AS) 
 
T = labeled quantity of indomethacin in mg 
C= concentration (µg per ml) in the standard solution 
D= concentration (µg per ml) in the test solution 
Based upon the labeled quantity per capsule and the extent of dilution 
Au and As are the absorbance of the solution from the capsule contents and the standard 
solution. 
7.4.5 Capsule weight variation [55, 57] 
        Individual weights of 20 capsules were taken and the average weight was calculated by 
using the following formula. 
                                              (Capsule weight -Average weight)    
         Weight variation =     -----------------------------------------------  × 100 
                                                  Average weight of capsules 
 
Weight variation should not be more than 7.5 % 
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7.4.6 Percentage yield [55, 79] 
              The yield was determined by weighing the pellets and then finding out the percentage 
yield with respect to the weight of the input materials. 
                The formula for calculation of percentage yield is  
                                                                Weight of pellets 
           Percentage yield (%)    =  ---------------------------------------- × 100 
                                                     Weight of drug + Weight of polymers 
 
7.4.7 Lock length [54, 79] 
 
After filling the capsules to determined lock length in these ten individual capsules were 
taken from each formulation trial batch and lock length was measured manually by using vernier 
calipers and average of ten capsules was noted. 
 
7.4.8 Loss on drying:  
It was done in Electronic Loss on Drying (LOD) apparatus (Sartorius, Germany). 
Weighed quantity of 1 gm sample was placed in the pan and the temperature was increased to 
105oC and the loss on drying in % was noted. 
 
7.4.9 IN-VITRO DRUG RELEASE STUDIES [86]:  
In-vitro drug release studies of indomethacin were carried by using apparatus USP test-Ι 
rotation basket method with a stirring speed 75 rpm at 37 ± 0.5°C in 750ml of 6.2 phosphate 
buffer for 24 hours. 5 ml of sample, with drawn at interval of 1, 2, 4, 6, 12, 24 hours with the 
replacement of equal volume of dissolution media. 
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Filtered the solution through millipore HYLP filter and these filtrate was measured at 319 
nm by UV spectrophotometer (UV-1700 SHIMADZU) 
The percentages of the labeled amount of indomethacin dissolved at the time specified 
acceptance table. 
                                                    Table No: 9 
Time (hours) Amount dissolved 
1 Between 10% and 25% 
2 Between 20% and 40% 
4 Between 35% and 55% 
6 Between 45% and 65% 
12 Between 60% and 80% 
24 Not less then 80% 
 
7.4.10 Comparison of Dissolution Profile with Marketed Product 
The dissolution profile (in USP 6.2 phosphate buffer) of optimized formula was compared 
with the dissolution profile of marketed product and the results were noted. 
7.5 Kinetics of drug Release [90, 91]: 
To analyze the mechanism of release and release rate kinetics of the dosage form, the 
data obtained were fitted into Zero order, First order, Higuchi and Peppas. Based on the R & n 
value, the best-fit model was selected. 
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1.  Zero order kinetics: 
 Zero order release would be predicted by the following equation 
 
At = A0 – K0t 
Where, 
 At  =  Drug release at time ‘t’. 
 A0  = Initial drug concentration 
 K0t  = Zero – order rate constant (hr-1). 
When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys Zero-order release kinetics, with a slope equal to K0. 
 
2.  First Order Kinetics: 
 First – order release would be predicted by the following equation 
 
Log C = log C0 – Kt / 2.303 
Where, 
 C = Amount of drug remained at time‘t’. 
 C0 = Initial amount of drug. 
            Kt = First – order rate constant (hr-1). 
When the data is plotted as log cumulative percent drug remaining versus time yields a 
straight line, indicating that the release follow first order kinetics.  The constant ‘K’ can be 
obtained by multiplying 2.303 with the slope values. 
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3.  Higuchi’s model: 
 Drug release from the matrix devices by diffusion has been described by following 
Higuchi’s classical diffusion equation. 
 
Q = [D /  (2 A - Cs) Cst]1/2 
Where, 
 Q    = Amount of drug released at time‘t’. 
            D    = Diffusion coefficient of the drug in the matrix. 
            A    = Total amount of drug in unit volume of matrix. 
 Cs   = Solubility of the drug in the matrix. 
  = Porosity of the matrix. 
 = Tortuosity. 
 t     = Time (hrs) at which ‘q’ amount of drug is released. 
Above equation may be simplified if one assumes that ‘D’, ‘Cs’, and ‘A’, are constant.  
Then equation becomes: 
                                                   Q = Kt1/2  
 When the data is plotted according to equation i.e. cumulative drug release versus square 
root of time yields a straight line, indicating that the drug was released by diffusion mechanism.  
The slope is equal to ‘K’. 
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4.  Korsmeyer equation / Peppa’s model: 
 To study the mechanism of drug release, it was further plotted in peppas equation as log 
cumulative % of drug released Vs time. 
 Mt / Ma = Ktn 
Where, 
 Mt / Ma = the fraction of drug released at time ‘t’. 
          K = Constant incorporating the structural and geometrical characteristics of the drug 
/ polymer system. 
           n = Diffusion exponent related to the mechanism of the release. 
 Above equation can be simplified by applying log on both sides 
                                                Log Mt / Ma  =  Log K + n Log t 
 When the data is plotted as log of drug released Vs log time, yields a straight line with a 
slope equal to ‘n’ and the ‘K’ can be obtained from y – intercept and range was shown in the 
table no.10 
Mechanism of Drug release as per Korsmeyer Equation / Peppa’s Model 
Table No.10 
S. No. N Value Drug release 
                 1 0.45 Fickian release 
                 2 0.45 <n <0.89 Non – Fickian release 
                 3 n> 0.89 Class II transport 
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7.6 Stability studies [59]: 
In any rationale design and evaluation of dosage forms, the stability of the active 
component must be major criteria in determining their acceptance or rejection. 
 
Reasons for stability studies: 
 There may be chemical degradation of the active drug leading to a substantial 
lowering the quantity of the therapeutic agent in the dosage form. 
 Although chemical degradation of the active drug may not be extensive, a toxic 
product may be formed in the decomposition process. 
 Instability of a drug product can lead to a decrease in its bioavailability. This can lead 
to a substantial lowering in the therapeutic efficiency of the dosage form. 
 
The drug release profile of batch F5 met the dissolution acceptance criteria to pass the 
amount of drug release test according to USP requirements. In this batch F5 was selected as 
optimized batches and subjected to further studies. The optimized batch F5 was charged for 
stability at 40°C/ 75% RH for 2 months. The drug release studies were repeated after storage for 
2 months at conditions like room temperature (RT) and 40°C/ 75% RH. 
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8. RESULTS AND DISCUSSION 
8.1 Drug- Excipient compatibility study:  
            Drug-Excipients compatibility study was carried out using various Excipients mentioned 
below table no.11. From the preformulation studies, it was observed that mixtures shown have 
no color change.   
Table No: 11 Physical observation 
S. No Composition details Initial Physical     Description 
25°C /60 % RH 
& 
40°C/ 75 % RH 
1st Week 2nd Week 3rd Week 
1 Indomethacin    Light yellowish  
        Powder    
NCC NCC NCC 
2 Indomethacin + 
Hydroxy propyl 
cellulose   
White to light 
yellowish powder NCC NCC NCC 
3 Indomethacin + 
povidone K30 
White to light 
yellowish powder NCC NCC NCC 
4 Indomethacin + low 
substitued hydroxy 
propyl cellulose 
White to light 
yellowish powder NCC NCC NCC 
5 Indomethacin + Ethyl 
cellulose (4cps)  
White to light 
yellowish powder NCC NCC NCC 
6 Indomethacin + 
sodium lauryl sulfate 
Light yellowish  
powder NCC NCC NCC 
7 Indomethacin + Talc  Light yellowish  
powder NCC NCC NCC 
8 Indomethacin + sugar 
spheres 
White to light 
yellowish powder NCC NCC NCC 
 
NCC: NO COLOUR CHANGE 
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8.2. Spectroscopic studies: 
8.2.1 UV spectroscopy (Determination of λmax) 
 
 
 The observed λmax was 319.60 nm. 
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8.2.2 IR Spectra of drug 
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   Interpretation of Indomethacin 
 
Frequency Groups Assigned 
3452.3 O-H Stretching 
3022.0 C-H Stretching 
1692.0 C=O Stretching 
1455.2 C=C Stretching 
925.8 C-H  Bending 
 
8.2.3 IR Spectrum of optimized formulation F-5 
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Interpretation F-5 
 
Frequency Groups Assigned 
3676.2 O-H Stretching 
3022.0 C-H Stretching 
1613.8 C=O Stretching 
1455.4 C=C Stretching 
925.8 C-H  Bending 
 
Discussion: 
When FT-IR Spectrum of indomethacin (pure drug) and optimized formulation of 
Indomethacin extended release pellets (F5) were compared, there were no major changes in the 
position of the spectrum. So it indicates absence of physical and chemical interactions of 
Indomethacin extended release pellets.  
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8.3 Indomethacin particle size 
                                 
 
Figure No.12 
Magnification of 400X 
Indomethacin micronized powder 
8.4 Evaluation of pellets of Indomethacin 
Table No: 12 
       
*Average values of the three determinations are given as results 
S. No 
Bulk density 
(g/cc) 
Tap density 
(g/cc) 
Carr’s Index 
(%) 
Hausner´s 
ratio 
      F-1 0.837±0.006 0.890±0.007 6.01±1.57 1.074±0.017 
      F-2 0.833±0.012 0.886±0.015 6.012±0.79 1.06±0.008 
      F-3 0.821±0.011 0.873±0.019 5.978±0.82 1.06±0.009 
      F-4 0.837±0.013 0.886±0.015 5.698±0.25 1.058±0.0005 
      F-5 0.845±0.012 0.899±0.008 6.209±0.63 1.049±0.030 
      F-6 0.873±0.014 0.918±0.008 4.866±0.73 1.036±0.017 
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8.4.1 Bulk Density & Tap Density 
Both bulk density and tapped bulk density results are shown in table no.12. The bulk 
density and tapped bulk density for all formulation varied in range of 0.821±0.011 to 
0.873±0.014 and 0.873±0.019 to 0.918±0.008. The value obtained lies within the acceptable 
range and with no much difference found between bulk density and tapped bulk density. These 
results may further influence the pellets dissolution. 
8.4.2 Compressibility Index & Hausner’s Ratio 
The percent compressibility of pellets was determined by Carr’s compressibility index as 
shown in table no.12.The percent compressibility for all formulation lies within the range of 
6.01±1.57 to 6.209±0.63. Hausner’s ratio was found to be in a range of 1.036±0.017 to 
1.074±0.017 which shows good flow property. 
8.4.3 Content uniformity: 
The results for uniformity of dosage units are presented in the table given below. The 
results were found to be within the limits (90 % to 110%). It shows that the drug was uniformly 
distributed. 
Table No: 13 
                
S. No Drug layered 
pellets of Content 
uniformity in (%) 
Extended layered 
pellets of Content 
uniformity in (%) 
      F-1       100.5 ± 0.75       99.1 ± 0.73 
      F-2       100.9 ± 0.66       99.4 ± 0.95 
      F-3       100.2 ± 0.37       99.0 ± 0.66 
      F-4       100.2 ± 0.45       98.3 ± 1.05 
      F-5       100.7 ± 1.19       99.1 ± 0.36 
      F-6        99.8 ± 0.16        98 ± 0.65 
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8.4.4 Yield & capsule lock length: 
The results for yield observed NLT 96% and capsule lock length were presented in the 
table given below.  
                                                               Table No: 14           
  Formulation  
      batches  
   Percentage        
     yield (%) 
   Capsule lock  
  Length in(mm)             
F1 99.36       19.30±0.10 
F2 98.81 19.33±0.09 
F3 99.47 19.35±0.10 
F4 98.3 19.31±0.09 
F5 98.71 19.33±0.11 
F6 97.84 19.32±0.09 
 
 
8.4.5 Weight variation & Loss on drying 
The weight of the capsule was fixed depending up the percentage of excipients used in the 
each formulation .Weight variation of the prepared capsules was within the limit .Mostly, the 
variation was within ± 7.5%.  
 
The prepared pellets of all the batches were evaluated for their moisture content. It is 
observed that the range around 1%. 
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Table No: 15 
 
  
 
 
 
 
*Average values of the three determinations are given as results 
8.4.6 Extended release formulation of Indomethacin pellets 
The in-vitro release studies of F1-F6 formulations were carried out by UV method and 
reported. The limits for indomethacin Extended release capsule as per USP are listed in the table 
USP limits for drug release for indomethacin extended release capsules    
 
                                                          Table No: 16 
Time (hours)        Amount dissolved 
1 Between 10% and 25% 
2 Between 20% and 40% 
4 Between 35% and 55% 
6 Between 45% and 65% 
12 Between 60% and 80% 
24 Not less then 80% 
 
S. No Weight(mg)± SD Loss on drying(%) 
F-1 409 ± 1.89 1.22 ± 0.02 
F-2 409 ± 2.63 1.20 ± 0.03 
F-3 409 ± 2.78 1.17 ± 0.02 
F-4 409 ± 2.52 1.18 ± 0.02 
F-5 415 ± 2.02 1.21 ± 0.02 
F-6 421 ± 1.73 1.18 ± 0.01 
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Table No: 17. In-vitro dissolution data of F1 
S. No 
Time 
(hrs) 
Amount of drug 
Release 
% drug release 
Cumulative % 
drug release 
1 1 29.08 38.77 38.77 
2 2 39.13 52.17 52.42 
3 4 48.12 64.16 64.50 
4 6 54.21 72.28 72.71 
5 12 67.45 89.94 90.42 
6 24 73.81 98.41 99.01 
 
 
 
Figure No: 13. In-vitro dissolution data of F1 
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Table No: 18.  In-vitro dissolution data of F2 
S. No Time  (hrs) 
Amount of 
drug 
Release 
% drug 
release 
Cumulative 
% drug 
release 
   1        1        27.25 36.33 36.33 
   2        2        35.46 47.28 47.52 
   3        4        45.37 60.49 60.80 
   4        6        53.90 71.86 72.26 
   5       12        61.52 82.02 82.50 
   6       24        72.78 97.04 97.59 
 
 
 
Figure No: 14. In-vitro dissolution data of F2 
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Table No: 19 In-vitro dissolution data of F3 
                 
S. No 
Time  (hrs) 
Amount of drug 
Release 
% drug 
release 
Cumulative % 
drug release 
1        1          21.62 28.83 28.83 
2        2          30.76 41.01 41.20 
3        4          42.10 56.13 56.40 
4        6          50.55 67.40 67.77 
5       12          59.54 79.38 79.83 
6       24          72.93 97.24 97.77 
 
 
 
Figure No: 15 In-vitro dissolution data of F3 
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Table No: 20 In-vitro dissolution data of F4 
                  
S. 
No 
Time (hrs) 
Amount of drug 
release 
% drug 
release 
Cumulative % 
drug release 
1 1 20.55 27.40 27.41 
2 2 31.59 42.12 42.31 
3 4 44.40 59.20 59.49 
4 6 47.66 63.54 63.94 
5 12 56.49 75.32 75.74 
6 24 72.24 96.32 96.82 
 
 
 
Figure No: 16 In-vitro dissolution data of F4 
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Table No: 21 In-vitro dissolution data of F5 
                  
S. 
No 
Time  (hrs) 
Amount of drug 
release 
% drug 
release 
Cumulative % 
drug release 
1 1 12.99 17.32 17.32 
2 2 23.50 31.33 31.44 
3 4 30.56 40.74 40.94 
4 6 39.95 53.26 53.53 
5 12 51.03 68.04 68.39 
6 24 72.63 96.84 97.29 
 
 
 
Figure No. 17 In-vitro dissolution data of F5 
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Table No: 22 In-vitro dissolution data of F6 
                   
S. No Time  (hrs) 
Amount of drug 
release 
% drug 
release 
Cumulative % 
drug release 
1 1 5.47 7.30 7.30 
2 2 18.14 24.19 24.23 
3 4 26.56 35.42 35.58 
4 6 34.51 46.02 46.25 
5 12 47.79 63.72 64.02 
6 24 67.44 89.93 90.35 
 
 
                                                               
Figure No: 18. In-vitro dissolution data of F6 
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 In the sugar spheres size (#30/35) was selected in the formulation used with ethyl 
cellulose (release retarding agent) and povidone K30 (binder), low substituted hydroxypropyl 
cellulose (binder), hydroxypropyl cellulose (binder), sodium lauryl sulfate (anionic surfactant), 
talc (lubricant) used in the extended release coating. 
 
In the formulation (F-1) the sugar sphere size (#30/35) are coated with drug layering 
containing ethyl cellulose(4cps) and povidone K30 and extended release (5%) coating buildup 
containing ethyl cellulose(4cps) and povidone K30 (1:1) ratio. Then the dissolution parameters 
are observed that they were not close to the U.S.P dissolution limits. This may be due to less 
binding capacity the polymer. 
 
So in the formulation (F-2) the ethyl cellulose (4cps) was kept constant and binder 
(povidone K30) is substituted with low substituted hydroxy propyl cellulose and the dissolution 
parameters are checked. In these formulation better results was observed when compared with 
(F-1) and they were close to the dissolution limits. But they did not exactly match with the 
dissolution limits of USP. This also may be due to improper binding of the polymer used. 
 
In the formulation (F-3) the low substituted  hydroxy propyl cellulose substituted with 
hydroxyl propyl cellulose and here also ethyl cellulose (4cps) was kept constant and the 
dissolution parameters are checked then the results are very close to the U.S.P dissolution limits 
than F-1 and F-2. 
 
From that to obtain better results in the dissolution (F-3) consider to formulation F-4 to 
change in the concentration of ethyl cellulose, hydroxyl propyl cellulose in the drug layered 
pellets and extended release coating is kept constant. Hence a very little change was observed in 
the dissolution timing (6th, 12th, 24th) hours.    
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Based on formulation (F-3) to formulate a further formulation (F-5) to concentration of 
ethyl cellulose (4cps) and hydroxypropyl cellulose was increased in extended release coating 
(7%) buildup in 1:1 ratio. Then the dissolution profile was checked these results were exactly 
matched with the U.S.P limits. 
 
 In the next formulation (F-6) the polymer concentration was increased than F-5. Here 
when the dissolution parameters were checked the 1st hour release did not satisfy the USP limits. 
The further results at different interval have passed the USP dissolution limits. 
 
 From the results obtained from the above formulations it shows that the formulation F-5 
is the best formulation among the all. 
  
 
 
Figure No: 19. Optimized formulation (F-5) Indomethacin pellets 
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Figure No: 20. Optimized formulation (F-5) Indomethacin capsule 
8.5 Comparison of dissolution Profile with marketed product  
   In which formulation (F-5) evaluation indicated that the dissolution profile of optimized 
formulation was comparable to the dissolution profile of marketed sample. It shows better 
release compared to market product.   
 
Dissolution Data of Market Sample Vs Optimized Formulation (F5) in 6.2 phosphate buffer   
Table No: 23 
Time in 
hours 
 
Ref(SANDOZ) 
Optimized 
formulation-F5 
Cumulative % of 
drug release 
Cumulative % of 
drug release 
1 11.41 18.21 
2 24.32 32.37 
4 45.67 41.84 
6 52.02 52.13 
12 60.81 67.49 
24 78.47 97.21 
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Figure No: 21 
8.6 Kinetic Studies: 
(i) Zero order kinetic plot  
Figure No: 22 
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Table No: 24 
 
Zero order 
R2 
0.9796 
 
(ii) First order kinetic plot 
Figure No: 23 
 
                                                                   Table No: 25  
First order kinetics 
R2 
0.9187 
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(iii) Higuchi plot  
                  
Figure No: 24 
 
 
 
                                                             Table No: 26 
  
Higuchi Plot 
R2 
0.9958 
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(iv) Korsmeyer-Peppas plot 
 
Figure No: 25 
 
 
 
 
                                                                                       Table No: 27 
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Release Kinetics study for optimized extended release pellets: 
The tables and figures showed the correlation coefficient of different kinetic model for 
optimized (F-5) formulation. Higuchi plots were found to be of highest linearity with correlation 
coefficient greater than that of the zero order kinetics and correspond to that of the first order 
kinetics indicating that the drug release mechanism from these pellets by diffusion method. 
Studies revealed that release was found to be very close to zero- order kinetics with a value of 
0.9796 indicating that the release was nearly independent of drug concentration. The in-vitro 
release was explained by higuchi model with a value of 0.9958 indicates a diffusion release. 
Moreover in-vitro release explained by korsmeyer-peppas equation also indicated a good 
linearity. The release exponent "n" was 0.454, which indicates the fickian diffusion model. 
8.7 COMPARATIVE IN –VITRO DRUG RELEASE PROFILE BEFORE AND AFTER  1  
MONTH  AND 2 MONTH STORAGE  AT(40°C / 75% RH.) OF   BATCH F5 
                                                             Table No: 28 
 
                                                      
Time in 
hours 
INITIAL 1 MONTH 2 MONTH 
Amount 
of drug 
release 
Cumulative 
(%) 
drug  
release 
Amount 
of                 
drug  
release 
Cumulative 
(%) 
drug  
release 
Amount 
of               
drug  
release 
Cumulative 
(%)                                      
drug  
release 
1 12.99 17.32 12.72 16.96 14.05 18.74 
2 23.50 31.45 24.03 32.15 24.85 33.26 
4 30.56 40.95 30.94 41.47 30.94 41.48 
6 39.95 53.54 40.73 54.58 38.91 52.16 
12 51.03 68.39 49.68 66.60 53.42 71.57 
24 72.63 97.03 72.63 97.28 73.84 98.93 
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Figure No: 26 
 
 
  8.7.1 DRUG CONTENT 
                                                     Table No: 29 
 
Time (month) 40°C / 75 % RH 
Initial 98.4 ± 1.09 
1st month 97.5 ± 1.05 
2nd month 97.03 ± 0.98 
 
*Average values of the three determinations are given as results 
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STABILITY STUDIES 
It is observed that no variation occurs in case of dissolution profile and drug content when 
it is stored in 40°C / 75% RH stability chamber. 
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9. CONCLUSION 
The present work was carried out to design and evaluate Indomethacin capsules 
containing extended release pellets. Indomethacin is a NSAID and is one of the most widely used 
drug for treating mild and severe pains.     
 
The combination of ethyl cellulose and other polymers the drug release rate increased due 
to a formation of a porous on the pellets. 
Formulation F-5 (containing ethyl cellulose 5% w/w and hydroxypropyl cellulose 
9%w/w) showed better release profile i.e. very low initial drug release in the first two hrs and 
afterwards the rate of drug release increased with almost complete release of the drug being 
achieved in 97.03% at 24 hrs respectively. Hence F-5 release profile was passed all USP test-1 
limits and further continuous for kinetic study and stability studies. 
Pellets technique using ethyl cellulose as the retardant has successfully extended the 
release of indomethacin from its pellets formulations. 
            In the present study, it was found that incorporation of hydroxypropyl cellulose in the 
pellets not only helped to provide good initial retardation in the release but also helps to enhance 
the overall release rate of the drug after a suitable lag time and also it will act as suitable binding 
property. 
The result of formulation (F-5) evaluation indicated that the dissolution profile of 
optimized formulation was comparable to the dissolution profile of marketed sample. It shows 
better release compared to market product.   
Optimized formulation F-5 was subjected to data obtained from stability studies indicate 
that there is no much change in the release profile and drug content of pellets. Hence the 
prepared pellets of formulation (F-5) were found to be stable. 
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